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The fast development of sequencing technologies has enabled rapid and large-
scale sequencing of human genomes. This leads to the availability of an increas-
ing number of high-quality whole-genome and exome sequencing datasets, and
provides excellent opportunities for human genomic research. One common ob-
servation from these genetic datasets is an extreme excess of rare variants. One
important way to utilize the information encoded in these rare variants is ex-
ploring their contribution to human complex diseases and traits. In Chapter 2,
I describe our pharmacological genetic research with the goal of identifying the
effects of rare genetic variants on patients’ response to lipid-lowering therapies
using a sequencing dataset of about 2,400 individuals. I discovered three sig-
nificant associations, showing that rare variants lower the efficacy of drugs for
different lipid levels. A second potential utilization of the observation of rare
variants in human genomes is studying the historical scenarios that gave rise to
them, specifically recent human population growth. Although many previous
studies of inferring such growth from the site frequency spectrum have shown
that human populations have undergone a recent epoch of fast growth in effec-
tive population size, one common limitation is that they assumed the speed of
growth to take the form of exponential growth, and the ensuing models leave
an excess amount of extremely rare variants. A more recent study introduced
a generalized model that allows the growth speed to be faster or slower than
exponential. However, only simulation software was available for generalized
models. In Chapter 3, I provide analytical expressions to accurately and effi-
ciently evaluate the site frequency spectrum and other summary statistics un-
der generalized models, as well as publicly available software that implements
these expressions. Applying my inference framework to the data from a large-
scale exome sequencing dataset, I found evidence that the recent growth of Eu-
ropeans is 12% faster than exponential. Beyond autosomal variants, genetic
variants on chromosome X also play a vital role in human complex diseases
and quantitative traits. Comparedwith autosomes, chromosome X showsmany
unique properties, with amost obvious and important one being thatmales only
have one copy of chromosome X. However, a vast majority of genome-wide as-
sociation studies have either ignored chromosome X, or analyzed chromosome
X using the same approaches for autosomal variants, potentially leading many
X-linked associations to remain unrevealed. In Chapter 4, I describe XWAS, a
software toolset tailored for the association analysis of chromosome X. It imple-
ments X-specific quality-control procedures as well as X-adapted single-marker
and gene-based tests. I further demonstrate the usefulness of XWAS by its ap-
plication to the analysis of multiple autoimmune datasets and the discovery of
several new X-linked genetic associations. Some of the associations exhibit sig-
nificant discrepancies in males and females, demonstrating the importance of
improving association methods to account for sex bias in chromosome X.
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CHAPTER 1
INTRODUCTION
The rapid reduction of human DNA sequencing costs has led to hundreds of
thousands of human genomes sequenced in the past decade, enabling the avail-
ability of an increasing number of large-scale whole-genome sequencing or ex-
ome sequencing datasets (e.g., [29, 41, 44, 108, 127]) and boosting in-depth re-
search on two major components of human genomes: rare variants, defined as
variants with the less common allele present in only < 1% or < 0.1% of the
sample, and X-linked variants, which are variants on chromosome X.
It is well observed that there is an extreme excess of rare variants in human
genomes when the number of sequences in a sample is large. As a specific ex-
ample, by analyzing the sequences of 200 genes in 14,000 individuals mostly
with European ancestry, a previous study reported that more than 70% of SNPs
have the minor allele presented in only one or two individuals [108]. This el-
evated proportion of rare variants has been suggested to be caused by recent
population growth [67, 72, 118]. It has also shaped a unique left-skewed pat-
tern in the site frequency spectrum (SFS) derived from the sequences of human
populations (e.g., [29, 41, 44, 49, 108, 127]), a very important summary statis-
tic commonly used in human genomic studies: it summarizes the proportion
of variants as a function of possible allele frequency counts in the sample. In
addition to the SFS, in the first section of Chapter 2, I revisited and expanded
the concept of a recently presented summary statistic [67], burden of private
mutation (BPM), as an alternative approach to quantify the amount of rare vari-
ants, especially singletons (SNPs with minor allele present in only one sequence
among all samples), in human genomes. This summary statistic can be trans-
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lated as the number of novel variants that are not present in the current sample
but are expected to be ascertained with a newly sequenced individual. Based
on the BPM calculated using real sequencing datasets, it was observed that after
whole-genome sequencing of 4,300 individuals from a certain European popu-
lation, more than 12,000 novel variants are expected with the sequencing of the
next individual, which constitutes 0.5% of all heterozygous sites in the newly se-
quenced individual [42, 43]. This number is orders of magnitude larger than the
expected value from a population that has remained a constant size throughout
history (i.e., no recent growth).
This huge amount of rare variants provides us with excellent opportunities
for exploration. A first potential utilization of these rare variants is elucidating
their contribution to human complex diseases and traits. In the second section
of Chapter 2, I describe our pharmacological genetics research that applied rare
variants-tailored association approaches to the analysis of targeted sequencing
data containing 5 lipid level related genes from about 2,400 patients to identify
rare genetic variants that affect individuals’ response to lipid-lowering thera-
pies. We discovered three significant associations, showing that rare variants
lower the efficacy of drugs for different lipid levels.
A second important use of the rare variants in human genomes is inference
of recent growth of effective population size in human populations. Rare variants
encode valuable information about very recent history of human populations
because rare variants are generally younger — due to more recent mutations
— than more common variants [67, 72, 118]. SFS is one of the most popular
summary statistics for this inference task. By matching the SFS of a model and
that derived from real sequencing data, many inference studies showed that
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several human populations have undergone a recent epoch of fast growth (e.g.,
[29, 44, 49, 50, 108, 127]). However, all of these studies assumed that the re-
cent growth takes the form of exponential function, which may have limited
the speed of growth considering the recent faster-than-exponential growth of
human census population size [29, 67, 117, 118]. A more recent study proposed
a novel generalized model that enables the growth to be slower or faster than
exponential [117, 118]. However, only simulation software were available to
simulate genomic sequences given a generalized model [117]. The tremendous
amount of time needed for simulation leaves the inference of population size
history using generalized models impractical. In Chapter 3, I provide analyt-
ical mathematical expressions that are numerically stable and allow accurate
and efficient evaluation the SFS and other summary statistics under general-
ized models, which were further implement in a publicly available software for
population size history inference. This new software exhibits a huge speed ad-
vantage over simulation-based approaches. Applying our inference framework
to the SFS of 4,300 individuals derived from a large-scale sequencing dataset
[41, 127], we found strong evidence that European population has undergone a
recent epoch of explosive growth that is about 12% faster than exponential.
Another substantial component of human genomes is the X chromosome
(X). Previous studies have suggested that X may play an important role in sex-
specific diseases such as autoimmune diseases [9, 85, 109, 115]. However, there
are many dissimilarities between autosomes and X. One most important fact is,
unlike autosomes, males have only one copy of X while females have two. This
suggests that improved models, methods and analysis software over traditional
ones designed for the association analysis of autosomal variants are needed for
studying the contribution of X to complex diseases and traits. However, most of
3
the genome-wide association studies (GWAS) to date have either excluded X or
analyzed it in the sameway as for the autosomes [142], which may lead to many
X-linked associations remain buried. In Chapter 4, I describe XWAS (chromo-
some X-Wide Analysis toolSet), a software toolset specifically designed for the
association analysis of X. This collaborative workwith other members of Keinan
lab includes X-tailored quality control procedures as well as various X-adapted
single-marker and gene-based tests. As an application, we used this new soft-
ware toolset to analyze multiple autoimmune datasets, and discovered several
new X-linked genetic associations. We found some of the associations show sig-
nificant differences in males and females, which further demonstrate the impor-
tance of improving association methods to account for sex-bias in chromosome
X.
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CHAPTER 2
EXCESS OF RARE VARIANTS DUE TO RECENT EUROPEAN
POPULATION GROWTHWITH APPLICATION TO ASSOCIATING
RESPONSES TO PHARMACOLOGICAL GENETICS OF LIPIDS
2.1 High Burden of Private Mutations Due to Recent Explosive
Growth in European Population
2.1.1 Abstract
Recent studies have shown that human populations have experienced a com-
plex demographic history, including a recent epoch of rapid population growth
that led to an excess in the proportion of rare genetic variants in humans today.
This excess can impact the burden of private mutations for each individual, de-
fined here as the proportion of heterozygous variants in each newly sequenced
individual that are novel compared to another large sample of sequenced indi-
viduals. We calculated the burden of private mutations predicted by different
demographic models, and compared with empirical estimates based on data
from the NHLBI Exome Sequencing Project and data from the Neutral Regions
(NR) dataset. We observed a significant excess in the proportion of private
mutations in the empirical data compared with models of demographic his-
tory without a recent epoch of population growth. Incorporating recent growth
into the model provides a much improved fit to empirical observations. This
phenomenon becomes more marked for larger sample sizes, e.g. extrapolat-
ing to a scenario in which 10,000 individuals from the same population have
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been sequenced with perfect accuracy, still about 1 in 400 heterozygous sites
(or about 6,000 variants) at the 10,001st individual are predicted to be novel, 18-
times as many as predicted in the absence of recent population growth. The
proportion of private mutations is additionally increased by purifying selec-
tion, which differentially affects mutations of different functional annotations.
The burden of private mutations for each individual, which are singletons (i.e.
appearing in a single copy) in a larger sample that includes this individual, is
predicted to be greatly increased by recent population growth, as well as by
purifying selection. Comparison with empirical data supports that European
populations have experienced recent rapid population growth, consistent with
previous studies. These results have important implications for the design and
analysis of sequencing-based association studies of complex human disease as
they pertain to private and very rare variants. They also imply that personal-
ized genomics will indeed have to be very personal in accounting for the large
number of private mutations.
2.1.2 Introduction
Many recent studies that sequenced large numbers of individuals have shown
that human populations have experienced a complex demographic history, in-
cluding a recent epoch of rapid growth in effective population size, although
estimates have varied greatly among studies [29, 41, 44, 49, 50, 108, 127]. The
growth of European population has recently been estimated to be exponential
with a rate of 2-5% per-generation increase in population size [41, 44, 127]. This
recent growth has resulted in an excess of rare single nucleotide variants (SNVs),
commonly defined as those with a minor allele (the less common of the two al-
6
leles) frequency (MAF) of less than 0.5% (or 1%) in a sample of individuals from
the same population (e.g. [45, 108]). The proportion of singletons (SNVs with
only one copy in the entire sample) is especially elevated due to this recent rapid
growth [41, 44, 67, 108, 127]. Consequently, the corresponding site frequency
spectrum (SFS), a summary statistic that indicates the proportion of variants of
each possible allele count in the sample, is skewed towards lower allele counts
(e.g. Figure 2.1).
A predicted consequence of the skew in the SFS due to population growth is
an increase in the burden of private mutations for each individual. We recently
defined this quantity as the proportion of heterozygous positions in each newly
sequenced individual that are novel, i.e., completely absent from a previously
sequenced sample from the same population [67]. In that previous paper, we
observed this burden to be higher in samples from populations of European
and East Asian descent than is predicted by previously estimated demographic
models that do not include an epoch of recent population growth [67]. However,
empirical estimates in that paper were based on a small sample size of less than
100 individuals, while the contribution of recent rapid growth is expected to be
more pronounced for larger sample sizes [29, 44, 49, 50, 67, 108, 127].
Here, we set out to (1) empirically estimate the burden of private mutations
from large samples of individuals of European ancestry, (2) compare these esti-
mates with predictions of previously proposed demographic models with and
without a recent epoch of exponential growth [44, 68], and (3) contrast SNVs
of different functions that are expected to have undergone different selective
effects. As purifying, negative selection on deleterious SNVs skews the SFS to-
wards rare variants [20, 38, 108, 71, 127], it can interact with the effect of recent
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population growth in increasing the burden of private SNVs, and differently so
for different functional categories. With the rapidly decreasing cost of sequenc-
ing, more and more high-quality sequencing data sets of large sample sizes and
improved accuracy of detecting rare variants become available. This provides
an excellent opportunity for a more accurate study of the burden of private mu-
tations. In this paper, we considered two such sequencing data sets of samples
from populations of European ancestry: the NHLBI Exome Sequencing Project
(ESP) [41, 127] and the Neutral Regions (NR) data set of putatively neutral re-
gions [44].
2.1.3 Methods
Datasets
Two data sets were used in this study. The NR data contains the genotypes of
493 European individuals with high homogeneity on relatively neutral SNVs of
15 genetic regions [44]. For quality purposes, all SNVs with less than 900 suc-
cessful genotype counts were filtered from the analysis. The remaining 1,746
SNVs constitute 95% of all variants [44]. The summarized data of 4,300 Eu-
ropean individuals from NHLBI Exome Sequencing Project records the minor
allele count and major allele count of each SNV identified in 15,585 genes on all
chromosomes (including chromosome X and Y) [41, 127]. In this analysis, we
combined all of the autosomal SNVs according to the 7 categories: intergenic,
intron, missense, nonsense, splice, synonymous and UTR. For quality purpose,
SNVs are filtered if the average read depth is less than or equal to 20 or the
successful genotype counts are less than 8,170 (95%).
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Subsampling Approach
In order to compare the SFS of data with different sample sizes (including the
different sample sizes across the SNVs caused by unsuccessful genotype counts
in the same data set), all the observed data were subsampled to 900 chromo-
somes. Following the strategy used in [68], for a SNV with jminor alleles out of
n successful genotype counts, the probability that it is of x minor alleles when
subsampled to m chromosomes is
P(x of m) =
1
1+ d(x,m  x)
 
( jx)(
n j
m x)
(nm)
+
( jm x)(
n j
x )
(nm)
!
(2.1)
where d(a, b) = 1 if a = b and d(a, b) = 0 if a , b, x = 0, 1, 2, . . . , bm2 c and (ab) B 0
if a < b.
Expected SFS and the Burden of Private Mutations for Demographic Models
The SFS of the three demographic models were calculated using exact compu-
tation [6] instead of simulations.
For a demographic model with constant population size, the burden of pri-
vate mutations can be derived under standard coalescent theory [99]. For con-
stant population size, the expected number of singletons of a folded SFS for a
sample of (n+ 1) diploid individuals is
E[h1] = q(1+
1
2n+ 1
) (2.2)
where q = 4Nm. The expected number of singletons that belong to one individ-
ual is
E[s] =
1
n+ 1
E[h1] =
2q
2n+ 1
(2.3)
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The expected number of heterozygote sites for the pair of sequences from one
individual E[h] = q. Thus the expected burden of private mutations is
E[a] =
E[s]
E[h]
=
2
2n+ 1
(2.4)
For variable population size, the general solution is
E[a] =
1
n+ 1
E[T2n+2,1] +E[T2n+2,2n+1]
E[T2,1]
(2.5)
where Tp,q stands for the total length of all branches in the coalescent tree which
have exactly q descents out of the total number of descents p. The branch lengths
are calculated by exact computation [6].
Computation of the Burden of Private Mutations Using Data Sets and Simu-
lations
For the NR data, for each of the 493 individuals, the burden of private mutations
a is directly calculated by the proportion of heterozygote sites which contain
singletons using the individual genotypes. Missing genotypes were abandoned.
The mean and standard deviation of a for this sample were then calculated by
a¯ =
1
n
n
å
i=1
ai; s(a) =
s
åni=1(ai   a¯)2
n  1 (2.6)
where n is the sample size and equals 493 here.
For ESP data and demographic models, as the individual genotypes were
not available, sequenceswere simulated by distributing theminor alleles of each
SNV to individuals randomly and independently. Unsuccessful genotype calls
(missing genotypes) were also distributed randomly to the individuals but were
distributed in pairs. In other words, the genotypes of each individual at each
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site either were both existent or both missing. Then awas calculated using these
simulated sequences in the same way as for the NR data.
For the demographic histories from which we can only get the SFS, a similar
method is applied. Namely we simulated a certain number of SNVs according
to the SFS and randomly assigned the minor alleles into individual sequences.
The simulated sequences were paired randomly to form the sequences of an
individual and a for each individual was then calculated.
To calculate a for a smaller sample size m, m individuals were randomly
chosen from the original n individuals and awas calculated using the genotypes
from these m individuals with the previously stated approach.
To study the effects of limited sites, a bootstrap approach was applied.
Specifically, we resampled individual SNPs with replacement 1,000 times. For
each bootstrap, we calculated the average a (ab,i) across all individuals and
these 1,000 averages were used to calculate the mean and standard deviation
of the bootstrap, the latter of which is an estimate of the standard error of the
sample:
a¯b =
1
nb
nb
å
i=1
ab,i; sb(a) =
s
ånbi=1(ab,i   a¯b)2
nb   1 (2.7)
where nb is the number of bootstraps and equals 1,000 here.
2.1.4 Results
In all analyses, we contrast three different demographic models and the fit of
their predictions to the NR data set [44] and to 7 functional categories of the
ESP data set [68, 127]. The three demographic models are (1) a population that
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has been of constant population size throughout history, (2) a model of Euro-
pean history that includes two population bottlenecks [68], and (3) a model of
European history with two bottlenecks, a recent change in population size, fol-
lowed by a recent epoch of rapid population growth [44] (Model II therein).
Comparison of Site Frequency Spectra
As the burden of private mutations is a function of the site frequency spectrum,
we first contrasted the site frequency spectra between three demographic mod-
els, the NR data [44], and the ESP data [68, 127] (Figure 2.1). In order to allow
comparison of the data sets with different sample sizes, as well as account for
missing genotype calls for each SNV, we probabilistically subsampled all data
to a sample size of 900 haploid chromosomes.
The proportion of singletons from demographic models (1) and (2) is greatly
lower than that in the observed data and that predicted by model (3), where
recent growth is incorporated (Figure 2.1). Among the categories of the ESP
data, categories that are expected to be more functional show a higher propor-
tion of singletons, e.g. intronic, intergenic, synonymous, and UTR SNVs have
a significantly lower proportion than non-synonymous, nonsense, and splice
SNVs (Figure 2.1), which is expected by the latter being more often deleterious.
These results recapitulate those from the ESP [41]. The proportion of singletons
in the SNVs from the NR data is lower than all categories of SNVs from ESP,
which is consistent with the former being designed such that variants are very
far from genes and putatively neutral [44], while the latter consists of variants
in and near protein-coding genes [41, 127], which are expected to more often
be targeted by purifying selection. Another factor that can contribute to this
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Figure 2.1: Site frequency spectra of demographic models and data with a
sample size of 900. The SFS for 3 demographic models, the Neutral Regions
(NR) data and 7 categories of the Exome Sequencing Project (ESP) data. To ad-
just for the different sample sizes in the two datasets, probabilistic subsampling
was applied to make all sample sizes equal to 900 chromosomes. Only the first
10 minor allele count categories are shown. For each minor allele count, from
left to right: constant population size, European history with 2 bottlenecks but
no growth [68], European history with recent growth (Model II in [44]), the NR
data, intergenic SNVs of the ESP data, intron SNVs of the ESP data, synony-
mous SNVs of the ESP data, UTR SNVs of the ESP data, missense SNVs of the
ESP data, nonsense SNVs of the ESP data and splice SNVs of the ESP data.
difference between the NR and ESP datasets is that the former aimed to cap-
ture a sample of homogenous ancestry, which corresponds to North-Western
European ancestry [44], while the latter consists of a broad sample of Euro-
pean Americans that exhibits a higher level of population structure [41, 127].
Increased population structure can lead to an increase in the proportion of rare
variants since some of these can be due to mutations that postdate the split of
the population captured by the different ancestries [44].
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Comparison of the Burden of Private Mutations
The predicted burden of private mutations for each individual from all demo-
graphic models and the empirical burden observed in the different data sets
and functional categories are presented in Figure 2.2. Across all sample sizes,
the burden of private mutations from empirical data is significantly higher than
that predicted by demographic models without growth. For example, based
on the results of the NR data, when 100 individuals have been sequenced, we
estimated that about 1.4% out of all heterozygous sites in the 101st sequenced
individual are novel, that is specific to the 101st individual and completely ab-
sent from the first set of 100 individuals. While models (1) and (2) predict only
1% in this scenario, model (3) is consistent with this estimate in the NR data.
For all demographic models and observed data, as more individuals are se-
quenced, the burden of private mutations decreases (Figure 2.2), because in-
creasing sample size makes it more probable that a variant has already been
discovered [67]. At the same time, the effect of recent growth itself on the bur-
den of privatemutations is muchmore pronouncedwith increasing sample size.
For example, for the NR data, when 492 individuals are sequenced, the esti-
mated burden of mutation from the 493rd sequenced individual is about 0.76%
(Table 2.1). The estimations from models (1) and (2) are only 0.20% and 0.26%,
respectively, about a third of empirical data, while model (3) matches the data
well. We note that this percentage varies greatly across individuals with the
relatively small number of SNVs in the NR data (Table 2.2).
When extrapolating the models to consider a scenario in which 10,000 in-
dividuals are sequenced, model (3) predicts the burden of mutations of the
10,001st individual to be 0.24% (Table 2.1), 24-times and 18-times that frommod-
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Figure 2.2: The burden of private mutations of demographic models and em-
pirical data. The burden of private mutations for the same demographic models
and empirical data as in Figure 2.1, using the same colors. This quantity corre-
sponds to the percentage out of all heterozygous sites in a newly sequenced
genome that are novel after n genomes have already been sequenced. Results
are presented for n = 100, n = 492, n = 1000, n = 4299 and n = 10000.
The value of 492 and 4299 are dictated by the sample size of the NR and ESP
dataset, respectively. For empirical data, mean percentage across individuals
is presented, together with error bars that denote  one standard error across
SNVs, estimated via bootstrapping (Methods). Double-slashes around a value
of 0 on the x-axis represent instances where data for that sample size is not
available in the respective dataset. Note that the range above 5% on the y-axis
is rescaled. The corresponding values in this figure are shown in Table 2.1.
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Table 2.1: Estimated mean and standard error of percentage of private muta-
tions for each individual.
Group n = 100 n = 492 n = 1000 n = 4299 n = 10000
Constant population
size model 0.995% 0.203% 0.100% 0.023% 0.010%
European history with
two bottlenecks 1.092% 0.257% 0.129% 0.031% 0.013%
European history with
recent growth 1.406% 0.750% 0.596% 0.349% 0.237%
NR data 1.444%(0.106%)
0.756%
(0.043%) NA NA NA
ESP intergenic 2.132%(0.123%)
1.125%
(0.049%)
0.835%
(0.034%)
0.496%
(0.019%) NA
ESP intron 2.233%(0.022%)
1.171%
(0.009%)
0.922%
(0.007%)
0.528%
(0.004%) NA
ESP synonymous 2.366%(0.026%)
1.252%
(0.012%)
0.974%
(0.009%)
0.573%
(0.005%) NA
ESP UTR 2.492%(0.079%)
1.305%
(0.034%)
1.004%
(0.025%)
0.596%
(0.014%) NA
ESP missense 4.482%(0.049%)
2.632%
(0.026%)
2.121%
(0.019%)
1.333%
(0.011%) NA
ESP nonsense 10.04%(0.92%)
7.37%
(0.68%)
6.00%
(0.50%)
4.46%
(0.38%) NA
ESP splice 14.36%(2.29%)
10.91%
(1.50%)
8.41%
(1.19%)
6.31%
(0.91%) NA
Table 2.2: The mean and standard deviation of the burden of private mutations
across individuals.
Group The burden of private mutations
Constant population
size model 0.208% (0.299%)
European history with
two bottlenecks 0.276% (0.352%)
European history with
recent growth 0.736% (0.614%)
NR data 0.758% (0.852%)
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els without recent growth that predict 0.010% and 0.013% based on models (1)
and (2), respectively (Table 2.1). This corresponds to almost 1 of 400 heterozy-
gous positions, which is equivalent to about 6,000 variants genome-wide. This
estimate is at least two orders of magnitude larger than the expected number of
de novo mutations of each individual (e.g. [119]). Hence, we predict that thou-
sands of novel variants will be discovered in each newly sequenced genome
even after tens of thousands of genomes from exactly the same population have
already been sequenced with perfect accuracy, and that these are rarely due to
de novo mutations.
Another important observation is that the burden of private mutations for
each individual calculated from all seven categories of the ESP data is consis-
tently higher than that from the NR data for all sample sizes (Figure 2.2). This
is consistent with the observation that the SFS of the ESP data are more left-
skewed than those of the NR data, which is consistent with decreased effect of
purifying selection and population structure on the latter. Comparing the differ-
ent ESP categories, splice and non-sense SNVs, which are expected tomost often
be deleterious, have the largest burden of private mutations across all sample
sizes. Similarly, the burden of all functional categories is ordered by common
expectations as to how often such mutations are expected to be functional. The
burden of private mutations captures a unique summary of the SFS that more
clearly shows the effect of purifying selection. For example, when n = 492,
the proportion of singletons is 46.2% for the ESP intergenic SNVs and 74.8% for
the ESP splice SNVs, which is 1.6-fold. In comparison, the burden of private
mutations for splice SNVs is about 9.7-fold of that for intergenic SNVs. This dif-
ference is even more pronounced when the sample size is larger, with 12.7-fold
different when n = 4299 (Figure 2.2).
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2.1.5 Discussion
Recent whole-genome sequencing data sets show that the proportion of rare
variants in large samples, especially singletons, is significantly elevated com-
pared with the prediction from the standard coalescent theory that assumes
a constant population size and from previous demographic models without
recent growth [29, 44, 67, 127]. Recent demographic modeling studies pre-
dict that humans have experienced a recent and rapid population growth,
which explains an increased proportion of singletons and other rare variants
[29, 44, 49, 50, 108, 127]. In this paper, we examined the burden of private
mutations for each individual, a statistic that reflects the relationship between
the relative proportions of singletons and more common variants contained in
a sample, with three demographic models and two data sets under different
sample sizes. We found that the burden of private mutations calculated from
empirical data and estimated from demographic models with a recent growth
is significantly higher than that estimated from models without recent growth
across all sample sizes. The discrepancy is predicted to be much more pro-
nounced for larger numbers of sequenced individuals. We showed that this
finding is consistent with a recent epoch of population growth. Moreover, we
found that the SNVs that are affected by stronger purifying selection will gen-
erally have larger burden of private mutations compared with more selectively
neutral SNVs, since they will have a higher proportion of singletons.
The proportion of private mutations that we consider translates to the num-
ber of novel variants expected to be ascertained with each newly sequenced
genome. Hence, our results have implications to sequencing-based association
studies of complex human diseases and other sequencing studies. For instance,
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we predict that even after 10,000 individuals from the exact same European
population have been perfectly sequenced, still 1 in 400 heterozygous sites will
be novel in each newly sequenced genome, which corresponds to discovering
about 6,000 new variants. This large expectation is due to the effect of the re-
cent rapid growth of European populations, which leads to this number being
at least 18-fold that predicted in the absence of such growth. Hence, careful
consideration must be given to private mutations in the design and analysis of
sequencing-based association studies and in quantifying the role played by rare
variants in complex human disease [19, 31, 40, 96, 98].
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2.2 Rare LPL Gene Variants Attenuate Triglyceride Reduction
and HDL Cholesterol Increase in Response to Fenofibric
Acid Therapy in Individuals with Mixed Dyslipidemia
2.2.1 Abstract
Individuals with mixed dyslipidemia have elevated triglycerides (TG), low
high-density lipoprotein cholesterol (HDL-C), and increased risk for coronary
disease. Fibrate therapy is commonly used to lower TG and increase HDL-C.
Common genetic variants are known to affect the response to fibrate therapy.
We sought to identify rare genetic variants (frequency  1%) in genes involved
in TG and HDL-C metabolism that affect the response to fenofibric acid (FA)
therapy. Four genes with a major role in HDL-C and TG metabolism APOA-I,
APOC-II, APOC-III and LPL were sequenced in 2,385 participants with mixed
dyslipidemia in a randomized, double-blind, active-controlled study compar-
ing therapy with FA alone, in combination with statins, or statin alone. Rare
variants collapsing or SKAT methods were used for the analysis. Synonymous
rare variants in the LPL gene were significantly associated with absolute HDL-C
change (P = 9 10 4) and TG percent change (P = 6.76 10 4) in those treated
with FA only. Participants with these rare variants had a 2 mg/dL increase in
HDL-C and 39 mg/dL decrease in TG as compared to 6.2 mg/dL increase in
HDL-C and 100 mg/dL decrease in TG in those without these variants. Rare
variants in the APOC-III gene were associated with a modest 3 mg/dL less re-
duction in APOB (P = 8.72 10 4) in those receiving FA and statin. In indi-
viduals with mixed dyslipidemia rare synonymous variants within LPL gene
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were associated with attenuated response to FA therapy while APOC-III rare
variants were associated with a modest effect on APOB response to FA-statin
therapy. These results should be replicated in a similar clinical trial for further
confirmation.
2.2.2 Introduction
Multiple studies have shown that genetic variants can affect triglycerides (TG)
and high-density lipoprotein cholesterol (HDL-C) response to fenofibrate. One
of the common uses of fibrates including fenofibric acid (FA) is to lower TG
and increase HDL-C in the population of mixed dyslipidemia (MD). Individu-
als with MD have high TG, low HDL-C, with or without high LDL-C, and are
at higher risk for coronary heart disease. Understanding the effect of specific
genetic variants on FA response can potentially help to predict its efficacy for
the individual patient. Multiple common genetic variants have been shown to
affect fibrate therapy [13, 14, 16, 23, 79, 88, 92], some of which had frequency as
much as 20% in the mixed dyslipidemia population [13, 92]. However, although
these genetic variants are frequent, their effect on drug response is usually mod-
est.
Rare genetic variants, defined as variants with a frequency of 1% or less,
have been previously shown to have a strong effect on lipid traits such as TG,
HDL-C and low-density lipoprotein cholesterol (LDL-C) [26, 27]. We have re-
cently shown that rare variants in the APOAV gene region have a significant
effect on FA response to therapy [12].
By means of pathway approach we sought to examine the association of rare
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genetic variants in a number of genes involved in TG and HDL-C metabolism
pathways with levels of apolipoprotein (APO) AI, TG, APOC-III, and HDL-C in
response to FA.
2.2.3 Methods
Study Population
Our study population included European-American participants from three
separate concurrent prospective, randomized, double-blind, clinical trials that
examined the efficacy of FA. A detailed description of the study design was in-
cluded in [63, 64]. Individuals with TG  150 mg/dL, HDL-C < 40 mg/dL in
men or< 50 mg/dL in women, and LDL-C 130 mg/dL were included. Study
participants were randomized into three groups receiving either FA monother-
apy, statin monotherapy, or statin-FA combination. Each study used a differ-
ent statin, rosuvastatin, atorvastatin, or simvastatin. After a 6-week washout
period, participants received a 12-week treatment. Lipid measurements were
obtained at the beginning and end of the treatment period. The basic charac-
teristics, including sex, age, body mass index (BMI), diabetes status, and the
baseline levels (APOAI, APOB, APOC-III, HDL-C, and TG) of the three treat-
ment groups are shown in Table 2.3.
Gene Selection
Four genes with pivotal roles in HDL-C and TG related pathways—APOAI,
APOC-II, APOC-III, and LPL—were included. Each of these genes has signif-
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Table 2.3: Baseline level statistics for FA, Statin and FA + Statin treatment
groups. P-value is of the test for no difference among the three treatment groups
using ANOVA F-test (age, BMI and all baseline levels) or c2 test (sex, diabetes).
Group FA Statin FA + Statin P-value
Number of
individuals 358 1104 923 -
Male:Female 156:202 544:560 426:497 0.12
Age 54.81 55.05 55.07 0.98
Diabetes
(With:Without) 77:281 250:854 204:719 0.89
BMI 31.8 6.1 32.0 6.2 31.9 6.2 0.88
APOAI
(mean  sd; mg/dl) 143.0 19.8 140.7 20.2 138.9 21.2 0.007
APOB
(mean  sd; mg/dl) 146.4 25.8 144.026.2 142.626.2 0.07
APOC-III
(mean  sd; mg/dl) 18.6 5.8 18.1 6.0 18.0 5.8 0.42
HDL
(mean  sd; mg/dl) 38.5 6.6 38.7 7.2 38.4 7.1 0.56
TG
(mean  sd; mg/dl) 272.6 136.6 275.3 145.2 273.3 139.0 0.93
icant impact on either HDL-C or TG metabolism and may be associated with
extreme lipid phenotypes such as chylomicronemia, hypertriglyceridemia, hy-
pobetalipoproteinemia, and elevated APOC-III. PPARA, the target gene for FA,
which is a peroxisome proliferator-activated receptor—alpha (PPAR-alpha) ag-
onist, was included as well.
Sequencing Protocol
Bidirectional sequencing was done at the Human Genome Sequencing Center
at Baylor College of Medicine using intron-based, exon-specific primers. Poly-
merase chain reactions (PCR) were performed in 8 ul containing 10 ng of ge-
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nomic DNA, 0.4 M oligonucleotide primers, and 0.7 Qiagen R PCR HotStar
Taq Master Mix containing buffer and polymerase. Cycling parameters were
95—15 min, then 95—45 s, 60—45 s, and 72—45 s for 40 cycles followed by a
final extension at 72 for 7 min. After thermocycling, 5 ul of a 1:15 dilution of
Exo-SAP was added to each well, and reactions were incubated at 37 C for 15
min prior to inactivation at 80 for 15 min. Reactions were diluted by 0.6, and 2
ul were combined with 5 ul of 1/64th Applied Biosystems R (AB) BigDyeTM
sequencing reaction mix and cycled as above for 25 cycles. Reactions were
precipitated with ethanol, resuspended in 0.1 mM EDTA, and loaded on AB
3730XL sequencing instruments using the Rapid36 run module and 3xx base-
caller. Single-nucleotide polymorphisms (SNPs) were identified using SNP De-
tector software [146].
Association Testing of Rare Variants
Baseline characteristics of the three treatment groups were compared using
ANOVA F-test (continuous characteristics, including age, BMI, and all baseline
levels) and c2 test (binary traits, including sex and diabetes status). Rare vari-
ants (frequency  1%) in the 5 sequenced genes were included in the analyses.
Rare variants within a gene were further classified to categories such as intronic,
missense, synonymous, promoter, and 5’ or 3’ untranslated region (UTR) vari-
ants. A total of 25 genes and gene categories (5 genes, 20 further split gene
categories) were used in the analyses. The number of the rare variants within
the 25 genes and gene categories, as well as the number of individuals that carry
these rare variants, is shown in Table 2.4.
Two complementary statistical approaches were used in this study, the Se-
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Table 2.4: Numbers of rare variants from the 25 gene and gene categories and
the number of individuals with at least one rare variant for each gene and gene
category.
Gene Category Number ofrare variants
Number of individuals with
at least one rare variant
APOAI Whole gene 4 3
Intron 4 3
APOC-II Whole gene 98 91
Intron 80 77
Synonymous 3 3
Missense 8 8
Nonsense 1 1
3’ UTR 2 2
5’ UTR 4 4
APOC-III Whole gene 12 11
Intron 4 4
Synonymous 5 5
Missense 3 2
LPL Whole gene 182 163
Intron 107 96
Synonymous 31 29
Missense 25 25
Nonsense 2 2
Splice region 17 16
PPARA Whole gene 152 116
Intron 52 46
Synonymous 26 23
Missense 65 60
Nonsense 1 1
5’ UTR 8 8
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quence Kernel Association Test (SKAT) and a simple collapsing approach. SKAT
is a rare-variant association analysis method for sequencing data, which allows
rare variants to influence the phenotype in different directions and with differ-
entmagnitude of effect and shows better computational efficiency and statistical
power over traditional collapsing methods [143]. This method was used to test
the association between rare variants and lipid level changes after therapy in
our study. The tested phenotypes were the absolute change in lipid levels (the
lipid level after therapy subtracting the baseline lipid level before therapy) and
percent change (the absolute lipid level change normalized by the baseline level
before therapy) of five lipids or lipid-related proteins (APOAI, APOB, APOC-
III, HDL-C and TG). For each analysis, six covariates were included: sex, age,
BMI, smoking status, diabetes status, and baseline lipid level. To increase the
statistical power of the analyses, each phenotype was tested in the three treat-
ment groups separately. To further increase power and accuracy, all SNPs with
missing rate  15% were excluded from each analysis, and all individuals with
missing phenotype or any missing covariate were also excluded from the anal-
yses. The association test for each phenotype with the 25 genes and gene cate-
gories was considered a separate analysis, and a threshold value of 2.0 10 3
(corresponding to a nominal p-value of 0.05) was considered significant after
Bonferroni correction for the 25 gene and gene categories tested.
Collapsing approaches, or “burden tests”, are commonly used for associa-
tion testing of rare variants [82, 102, 103]. In our study, this method was applied
to show the dominating direction of the significant associations found by SKAT
method, as SKAT allows rare variants to influence the phenotype in different di-
rections and thus does not show the dominating direction of the association. We
collapsed the rare variants by counting the number of rare variants in each gene
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and gene category. Multivariate linear regression was then performed between
the number of rare alleles and the tested phenotype using R. The regression
coefficient obtained from this method is the magnitude of reduction (if the co-
efficient is negative) or increase (if the coefficient is positive) in the lipid level
change on average when an individual has one more rare variant as compared
with the individuals without any rare variant.
2.2.4 Results
Baseline characteristics of each of the three treatment groups are presented in
Table 2.3. There was no significant difference at baseline between the three treat-
ment groups other than baseline level of APOAI, which was slightly higher in
the FA only treatment group. As expected, there were no differences in baseline
HDL-C, TG, APOB, or APOC-III levels.
We examined the association of the 25 genes and gene categories with each of
the 10 phenotypes (absolute lipid level change and percentage lipid level change
of the five lipids or lipid proteins) in the three treatment groups. The Q-Q plots
for p-values of the association studies are shown in Figure 2.3. Power calcula-
tion shows that SKAT method has enough power to detect significant associa-
tions with at least five rare variants. Three significant associations were found
using SKAT method. These significant results were then further confirmed by
100,000 permutations.
The synonymous rare variants in the LPL gene region were found to be
significantly associated with the absolute HDL-C change (P = 9.00  10 4,
Pc = 0.023 after Bonferroni correction, Pperm = 0.00196 using permutation test)
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Figure 2.3: Q-Q plots for the P-values from association analyses with SKAT
method. Left: the P-values are from the association analyses of the absolute
lipid level changes of APOAI, APOB, APOC-III, HDL-C and TG; Right: the P-
values are from the association analyses of the percentage lipid level changes of
APOAI, APOB, APOC-III, HDL-C and TG.
and TG percent change (P = 6.76 10 4, Pc = 0.017 after Bonferroni correction,
Pperm = 0.00189 using permutation test) (Table 2.5 and Table 2.6) in the FA treat-
ment group. No association was detected with APOAI response in any of the
treatment groups.
Table 2.5: Significant association between LPL coding synonymous gene cate-
gory and absolute change in HDL-C in FA group adjusted for sex, age, BMI,
smoking, diabetes and baseline HDL-C level.
Group Number ofindividuals
Number of
rare variants P-value by SKAT
FA 318 5 9.00 10 4
FA + Statin 834 11 0.50
Statin 1019 15 0.88
Participants with synonymous rare variants in the LPL gene region receiving
FA only therapy had an attenuated increase of 2 mg/dL in HDL-C as compared
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Table 2.6: Significant association between LPL coding synonymous gene cat-
egory and percentage change in TG in FA group adjusted for sex, age, BMI,
smoking, diabetes and baseline TG level.
Group Number ofindividuals
Number of
rare variants P-value by SKAT
FA 345 5 6.76 10 4
FA + Statin 899 11 0.48
Statin 1071 15 1.00
to 6.2 mg/dL increase in those without rare LPL synonymous variants (Table
2.7). The opposite pattern was observed for TG response in those receiving
FA only therapy. Participants with synonymous rare variants in the LPL gene
region had TG reduction of 39 mg/dL as compared to 100 mg/dL reduction in
those without rare LPL synonymous variants (Table 2.8).
Table 2.7: Mean HDL-C before treatment, after treatment and change in HDL-
C for individuals in FA group with and without rare variants in LPL coding
synonymous gene category.
Group
Mean  SE
before treatment
(mg/dL)
Mean  SE
after treatment
(mg/dL)
Mean  SE
change
(mg/dL)
Without rare variants
(n = 313) 38.56 0.38 44.78 0.55 6.22 0.35
With rare variants
(n = 5) 39.88 1.65 41.80 6.08 2.00 6.50
Combination of all of the rare variants in the APOC-III gene in the FA and
statin combined therapy group were found to be significantly associated with
the absolute change in APOB (P = 8.72  10 4, Pc = 0.022 after Bonferroni
correction, Pperm = 0.00469 using permutation test) (Table 2.9).
Participants with rare variants in the APOC-III gene in the FA-statin com-
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Table 2.8: Mean TG before treatment, after treatment and change in TG for indi-
viduals in FA group with and without rare variants in LPL coding synonymous
gene category.
Group
Mean  SE
before treatment
(mg/dL)
Mean  SE
after treatment
(mg/dL)
Mean  SE
change
(mg/dL)
Without rare variants
(n = 313) 272.46 7.82 172.27 5.07  100.19 6.48
With rare variants
(n = 5) 279.60 65.31 242.20 54.53  39.40 40.19
Table 2.9: Significant association between gene APOC-III and absolute change
in APOB in FA and statin combined group adjusted for sex, age, BMI, smoking,
diabetes and baseline APOB level.
Group Number ofindividuals
Number of
rare variants P-value by SKAT
FA + Statin 887 7 8.72 10 4
FA 342 0 –
Statin 1055 5 0.62
bination group had a 53 mg/dl reduction in APOB levels compared with 56
mg/dl in those without rare variants in APOC-III. However, there was no dif-
ference in LDL-C reduction between the groups with and without the APOC-III
rare variants in all therapy groups (Table 2.10). The information of rare variants
involved in the significant associations is listed in Table 2.11 and Table 2.12.
We used the beta coefficients from the simple collapsing method to interpret
the significant results found by the SKAT method. For the FA group, the indi-
viduals with rare variants in LPL synonymous category tended to have lower
absolute change in HDL-C and higher percentage change in TG compared with
those without any rare variant (Figure 2.4). For the combination therapy group,
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Table 2.10: Mean APOB before treatment, after treatment and change in APOB
for individuals in FA and statin combined group with and without rare variants
in APOC-III gene.
Group
Mean  SE
before treatment
(mg/dL)
Mean  SE
after treatment
(mg/dL)
Mean  SE
change
(mg/dL)
Without rare variants
(n = 881) 142.63 0.88 86.14 0.87  56.49 0.95
With rare variants
(n = 6) 138.00 13.57 85.33 7.34  52.67 8.93
Table 2.11: Rare variants of FA group in LPL coding synonymous gene category.
Chromosome Position Minor allele Minor allelefrequency
Number
of copies
8 19850095 T 2.23 10 4 1
8 19857642 A 2.15 10 3 1
8 19853655 C 1.31 10 3 2
8 19856023 G 2.20 10 4 1
Table 2.12: Rare variants of FA and statin combined group in APOC-III gene.
Chromosome Position Minor allele Minor allelefrequency
Number
of copies
11 116206523 T 1.10 10 3 3
11 116206603 A 2.19 10 4 1
11 116206626 G 4.38 10 4 1
11 116206725 G 6.59 10 4 2
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the individuals with rare variants in APOC-III gene tended to have higher ab-
solute change in APOB compared with those without any rare variant (Figure
2.4). The corresponding information for simple collapsing method, including
the Q-Q plot for the simple collapsing method is shown in Table 2.4 and Figure
2.5.
2.2.5 Discussion
In the current study we show that rare synonymous LPL gene variants can at-
tenuate the effects of FA therapy on TG reduction and HDL-C increase in indi-
viduals withmixed dyslipidemia. In addition, rareAPOC-III gene variants were
associatedwith amodest attenuation in APOB reduction following combination
therapy with statins and FA in the study population.
Rare genetic variants are fairly common but are usually unique for each in-
dividual. Overall the frequency of a specific rare variant is very low, but the
probability of having some type of a unique rare variant is high. In fact, the
overall population frequency of rare variants in a specific gene (i.e. total num-
ber of rare variants which are different) is higher than the frequency of many
of the common SNPs in that gene. It has been previously shown that common
SNPs in the LPL gene affect baseline triglyceride and HDL-C levels as well as
response to fibrates. The additional information in this study about the effect
of rare LPL gene variants and response to FA adds to the understanding of how
LPL gene variants affect response to fibrate therapy.
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Figure 2.4: Box plots for the three significant associations. Left: the box plot
for the association between the synonymous rare variants in the LPL gene re-
gion and the absolute change of HDL-C in FA group. 5 individuals have 1 rare
allele in LPL synonymous category. Individuals with rare variants tend to have
lower increase in HDL-C. Middle: the box plot for the association between the
synonymous rare variants in the LPL gene region and the percentage change of
TG in FA group. 5 individuals have 1 rare allele in LPL synonymous category.
Individuals with rare variants tend to have lower percentage reduction in TG.
Right: the box plot for the association between the variants in theAPOC-III gene
region and the absolute change of APOB. 5 individuals have 1 rare allele and 1
individual has 2 rare alleles. Individuals with rare variants tend to have lower
reduction in APOB.
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Figure 2.5: Q-Q plots for the P-values from association analyses with SKAT
method. Left: the P-values are from the association analyses of the absolute
lipid level changes of APOAI, APOB, APOC-III, HDL-C and TG; Right: the P-
values are from the association analyses of the percentage lipid level changes of
APOAI, APOB, APOC-III, HDL-C and TG.
TG reduction is thought to be a risk factor for coronary disease, as previ-
ously shown in a large Mendelian randomization study using common SNPs in
the LPL gene region [131]. Although therapy with fibrates did not reduce coro-
nary disease risk in the general study population in large clinical trials such as
in the ACCORD LIPD trial, it did reduce coronary events in those with mixed
dyslipidemia for those with absolute levels of TG > 204 mg/dL and HDL-C <
36 mg/dL [129]. Thus, identifying genetic factors that influence response to fi-
brates in the mixed dyslipidemia population has the potential to predict which
patients will have higher TG reduction and larger HDL-C increase with FA ther-
apy. This has the potential to identify which patients are most likely to derive
coronary risk reduction fromfibrate therapy. We suggest that rare variants in the
LPL gene region may contribute to the coronary risk reduction effect of fibrates
previously observed in the population of individuals with mixed dyslipidemia.
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The LPL enzyme plays a pivotal role in TG metabolism. TG hydrolysis is
facilitated by a complex interaction of LPLwith various proteins such as APOC-
II, APOC-III, APOAV, and others. There are well known recessive, single gene
disorders that involve APOC-II and LPL genes and result in significant hyper-
triglyceridemia [62]. In these conditions there is little or no response to fibrates,
as there is almost no residual LPL function. Common and rare SNPs may po-
tentially have a similar but milder effect.
A common intronic SNP, rs320, was examined in a Chinese population re-
ceiving fenofibrates and was associated with a lesser TG reduction in homozy-
gotes as compared with wild type genotypes. Although the rs328 was not ex-
pected to change the gene product, it was thought to reside in a protein binding
region that indirectly effects the protein production [23]. In the current study, we
show that rare synonymous LPL gene variants that are not expected to change
protein structure can attenuate the TG reduction and HDL-C increase effects of
fenofibrate.
FA is a peroxisome proliferator-activated receptor agonist that has multiple
effects. It reduces TG by increasing LPL gene transcription and increases APOAI
and HDL-C levels [135]. The rare LPL gene variants identified in our study may
potentially affect FA response by interfering with PPAR-alpha activation of LPL
transcription resulting in a smaller net TG reduction and HDL-C increase.
An additional finding was the association of the total rare variants in the
APOC-III gene with APOB response in participants receiving the combination
of statins and FA. This was a modest effect, and there is no known direct bi-
ological relationship between APOC-III and APOB. APOC-III is an important
cofactor for TG hydrolysis by the LPL enzyme, and a possible explanation for
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the effect of APOC-III rare variants on APOB response could be related to very
low-density lipoprotein particle metabolism by the LPL enzyme.
Our study has limitations. The study was a randomized active-controlled
trial with themost significant associations identified in the FA only groupwhich
had relatively a small sample size. This limitation was approached by using the
SKAT statistical approach for which this sample size was sufficient and permu-
tation testing that did further confirm the results. However, replication of the
significant association in an independent randomized prospective clinical trial
would be important to further confirm the study’s results.
In conclusion, we identified rare genetic variants that affect the response to
FA and its combination with statins. Our analysis suggests that synonymous
variants within the LPL gene region may be associated with reduced response
to FA in individuals withmixed dyslipidemia, whichmay attenuate its potential
effect to reduce coronary disease.
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CHAPTER 3
INFERENCE OF SUPER-EXPONENTIAL HUMAN POPULATION
GROWTH VIA EFFICIENT COMPUTATION OF THE SITE FREQUENCY
SPECTRUM FOR GENERALIZEDMODELS
3.1 Abstract
The site frequency spectrum (SFS) and other genetic summary statistics are at
the heart of many population genetic studies. Previous studies have shown that
human populations have undergone a recent epoch of fast growth in effective
population size. These studies assumed that growth is exponential, and the en-
suing models leave an excess amount of extremely rare variants. This suggests
that human populations might have experienced a recent growth with speed
faster than exponential. Recent studies have introduced a generalized growth
model where the growth speed can be faster or slower than exponential. How-
ever, only simulation approaches were available for obtaining summary statis-
tics under such generalized models. In this study, we provide expressions to
accurately and efficiently evaluate the SFS and other summary statistics un-
der generalized models, which we further implement in a publicly available
software. Investigating the power to infer deviation of growth from being ex-
ponential, we observed that adequate sample sizes facilitate accurate inference;
e.g., a sample of 3,000 individuals with the amount of data expected from exome
sequencing allows observing and accurately estimating growth with speed de-
viating by  10% from that of exponential. Applying our inference framework
to data from the NHLBI Exome Sequencing Project, we found that a model with
a generalized growth epoch fits the observed SFS significantly better than the
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equivalent model with exponential growth (P-value = 3.85  10 6). The esti-
mated growth speed significantly deviates from exponential (P-value 10 12),
with the best-fit estimate being of growth speed 12% faster than exponential.
3.2 Introduction
Summary statistics of genetic variation play a vital role in population genetics
studies, especially inference of demographic history. In particular, the site fre-
quency spectrum (SFS) is a vital summary statistic of genetic data and is widely
utilized by many demographic inference methods applied to humans and other
organisms [8, 37, 50, 87, 99]. Some other demographic inference methods are
based on sequential markov coalescent and utilize the most recent common an-
cestor (TMRCA) and linkage disequilibrium patterns [53, 83, 95, 121, 122]. As
another example, several studies used the average pairwise difference between
chromosomes [4, 47, 51] and the SFS [69] to study the relative effective popu-
lation sizes between the human X chromosome and the autosomes. The wide
application of such genetic summary statistics stresses the need for their fast
and accurate computation under any model of demographic history, instead of
their estimations via simulations or approximations (e.g., [50, 55]).
Several recent demographic inference studies showed evidence that human
populations have undergone a recent epoch of fast growth in effective popula-
tion size [29, 44, 49, 50, 108, 127]. However, the above studies assumed that the
growth is exponential. The observation of huge amount of extremely rare, pre-
viously unknown variants in several sequencing studies with large sample sizes
[41, 108, 127] and the recent explosive growth in census population size suggests
38
that human population might have experienced a recent super-exponential
growth, i.e. growth with speed faster than exponential [29, 67, 117, 118]. Hence,
recent studies presented a new generalized growth model that extends the pre-
vious exponential growth model by allowing the growth speed to be exponen-
tial or faster/slower than exponential [117, 118]. Modeling the recent growth by
this richer family of models holds the promise of a better fit to human genetic
data, and can also be applicable to other organisms that experienced growth.
However, only simulation approaches are currently available for evaluating
such a generalized growth demographic model [117], which makes inference
of demographic history computational intractable.
In this study, we first provide a set of explicit expressions for the computa-
tion of five summary statistics under a model of any number of epochs of gen-
eralized growth: (1) the time to the most recent common ancestor (TMRCA), (2)
the total number of segregating sites (S), (3) the site frequency spectrum (SFS),
(4) the average pairwise difference between chromosomes per site (p), and (5)
the burden of private mutations, BPM (a), a summary statistic that has been
recently introduced as sensitive to recent growth [42, 67]. We also introduce
a new software package, EGGS (Efficient computation of Generalized models’
Genetic summary Statistics), that implements these expressions and facilitates
fast and accurate generation of these summary statistics. We show that the nu-
merically computed summary statistics match well with simulation results, and
facilitates computation that is orders of magnitudes faster than that of simula-
tions. By performing demographic inference on the SFS generated from simu-
lated sequences, we then explored how many samples are needed for recover-
ing parameters of a recent generalized growth epoch. Finally, we applied the
software to investigate the nature of the recent growth in humans by inferring
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demographic models using the SFS of synonymous variants of 4,300 European
individuals from the NHLBI Exome Sequencing Project [41, 127].
3.3 Materials and Methods
3.3.1 Generalized Demographic Models
A demographic model N(T) describes the changes of effective population size
N against time T. We consider time, measured in generations, as starting from
0 at present and increasing backward in time. Furthermore, we consider the
families of demographicmodels that are constituted by any number of epochs of
generalized growth, along the lines of [7]. More formally, there exists a minimal
positive integer L such that the demographic history of a population can be split
into a model with L+ 1 epochs that are split by L ordered different time points
T1, T2,    , TL (T0 = 0 < T1 < T2 <    < TL < TL+1 = ¥), with the kth epoch
starting from Tk 1 and lasting through Tk (thus the last epoch starts at time TL
and continues into indefinite past, TL+1 = ¥). Such a history is considered as a
generalized model if the population size in each epoch N(Tk 1  T < Tk) can
be described by the following differential equation regarding time T [117, 118]:
dN
dT
=  rkNbk , (3.1)
where k = 1, 2,    , L+ 1. Each epoch can hence capture a variety of changing
patterns in effective population size. Specifically, if rk = 0, this epoch is of
constant population size. When rk , 0, bk controls the growth speed of this
epoch: (1) if bk = 1, the epoch is of exponential growth (rk > 0) or decline
(rk < 0) with rate rk; (2) if bk > 1, the epoch is of faster-than-exponential (super-
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exponential) growth (rk > 0) or decline (rk < 0); (3) if bk < 1, the epoch is
of slower-than-exponential (sub-exponential) growth (rk > 0) or decline (rk <
0). Linear growth or decline is also a special case of generalized models when
bk = 0. An illustration of a generalized model with 5 epochs is provided in
Figure 3.1, with more detailed explanation and illustrations in Appendix A.2
and Figure A.1.
Figure 3.1: Illustration of an example of a generalized demographic model.
This model consists of 5 epochs (starting from present): (1) Faster-than-
exponential (b > 1) growth (looking forward in time) from N1,f to N1,i between
T0 = 0 and T1; (2) Linear decline (a special case of generalized growth when
b = 0) from N2,f to N2,i between T1 and T2; (3) Exponential growth (a special
case of generalized growth when b = 1) from N3,f to N3,i between T2 and T3;
(4) Slower-than-exponential (b < 1) decline from N4,f to N4,i between T3 and
T4; (5) Constant population size (a special case of generalized growth when
r = 0) at N5,i = N5,f starting from T4 and lasts indefinitely backward in time
(T5 = ¥). The ending population size of the previous epoch is not necessarily
the beginning population size of the next epoch (e.g., N2,f , N3,i, N4,f , N5,i),
corresponding to an instantaneous population size change at that time.
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The solution to Equation (3.1) is [117, 118]
N (T) =
8><>:

N1 bkk,i   rk (T   Tk 1) (1  bk)
 1
1 bk , bk , 1
Nk,ie rk(T Tk 1), bk = 1
(3.2)
where Nk,i is the initial population size of the kth epoch. Each epoch k is defined
by 4 parameters: the starting population size Nk,i, the ending population size
Nk,f, the duration of the epoch (Tk   Tk 1) and the growth speed parameter bk.
The growth rate parameter, rk is an immediate function of these parameters,
rk = rk (Nk,i,Nk,f, bk, Tk   Tk 1), and hence does not need to be provided as an
independent variable in defining the changes in effective population size during
an epoch. Note that Nk+1,i, the starting population size of the (k + 1)th epoch
is not necessarily the same as Nk,f, the ending population size of the kth epoch.
Specifically, if Nk+1,i , Nk,f, there is an instantaneous change in population size
at time Tk.
3.3.2 Explicit Expressions for Summary Statistics of Demo-
graphic Models Under Arbitrary Population Size Func-
tions
In this section, we briefly summarize the main results from previous studies
that are used to evaluate the expected value of the summary statistics. Under
Kingman’s standard coalescent [73, 74], given a demographic model N(T), the
expected time of the most recent common ancestor E

TpMRCA

can be calculated
by [110]
E

TpMRCA

=
p
å
j=2
Apj yj , (3.3)
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where the superscript p is the number of chromosomes (i.e. twice the sample
size for diploids), yj is the expected time of the first coalescent event when there
are j chromosomes at present and Apj are constants [111, 124, 125] provided
in Appendix A.3. Without loss of generality, we consider the case of diploid
individuals, where there are 2N(T) chromosomes at any generation T, and use
the notation N (T) = 2N (T). Then yj is expressed by the following equation:
yj =
Z ¥
0
T
( j2)
N (T)e
  R T0 ( j2) dsN (s) dT = Z ¥
0
e (
j
2)L(T) dT, (3.4)
where L(T) =
R T
0
ds
N (s) .
The expected full normalized SFS E [p] =

E

x
p
1

,E

x
p
2

, . . . ,E
h
x
p
p 1
i
can be computed by the following set of equations [110]:
E

x
p
i

=
E

`
p
i

E [Lp] ;E

`
p
i

=
p
å
j=2
Wpi,jyj;E [Lp] =
p
å
j=2
Vpj yj, (3.5)
where `pi is the length of branches in the genealogy that have i descendants
(i = 1, 2,    , p  1) and Lp = åp 1i=1 `pi is the total length of all branches in the
coalescent tree. The quantitiesVpj andW
p
i,j are constants [110], whichwe provide
in Appendix A.3.
Naturally, the expected number of segregating sites is given by
E [S] = m0LE [Lp] , (3.6)
where m0 is the mutation rate per site per generation and L is the length of the
locus under consideration. The average pairwise difference between chromo-
somes per site E [p] can be calculated by
E [p] = 2m0E
h
Tp=2MRCA
i
. (3.7)
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The expected burden of private mutations a at diploid sample size of  p
2   1

, defined as the proportion of heterozygous sites in a new diploid in-
dividual that are homozygous in the previous
  p
2   1

individuals, E
h
a p
2 1
i
can be computed by [42]
E
h
a p
2 1
i
=
2
p [1+ d (1, p  1)]
E

`
p
1

+E
h
`
p
p 1
i
E

`21
 , (3.8)
where d(, ) is Kronecker delta function.
The detailed description of the five summary statistics mentioned above is
included in Appendix A.1.
3.3.3 Evaluation of the Expected Time to the First Coalescent
Event under Generalized Models
The core of evaluating the summary statistics lies in finding feasible and nu-
merically stable functions for calculating yj, the expected time of the first co-
alescent event when there are j chromosomes at present. Previous studies
give explicit expressions of yj for a demographic model constructed by expo-
nential and constant-size epochs [8, 110]. In this study, we give a compre-
hensive set of yj formulas for generalized models introduced above. Define
fkj B
R Tk
Tk 1
e (
j
2)L(T) dT, then yj = åL+1k=1 f
k
j , where (L+ 1) is the total number of
epochs. The quantity fkj can be computed by the following set of equations:
(1) If rk = 0 or bk = 0, rk , 0:
fkj =
8><>:
1
( j2)
h
e (
j
2)L(Tk)Nk,f logNk,f   e (
j
2)L(Tk 1)Nk,i logNk,i
i
, rk + (
j
2) = 0
1
rk+(
j
2)
h
e (
j
2)L(Tk 1)Nk,i   e (
j
2)L(Tk)Nk,f
i
, rk + (
j
2) , 0
;
(3.9)
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(2) If bk > 0, rk > 0 or bk = 1, rk < 0:
fkj =
1
( j2)
"
Nk,iU
 
2  1
bk
,
( j2)
bkrk
N bkk,i
!
e (
j
2)L(Tk 1)  
Nk,fU
 
2  1
bk
,
( j2)
bkrk
N bkk,f
!
e (
j
2)L(Tk)
#
; (3.10)
(3) If bk < 0, rk > 0:
fkj =
1
( j2)
"
Nk,fM
 
2  1
bk
,
( j2)
bkrk
N bkk,f
!
e (
j
2)L(Tk)  
Nk,iM
 
2  1
bk
,
( j2)
bkrk
N bkk,i
!
e (
j
2)L(Tk 1)
#
(3.11)
The expressions of function L(T) are given in Appendix A.5. The function
U (b, x) B xU(1, b, x) = x R ¥0 e xt(1 + t)b 2 dt, where U(a, b, x) is the conflu-
ent hypergeometric function of the second kind [48]. The function M(b, x) B
x
b 1M(1, b, x) = x
R 1
0 e
xt(1  t)b 2 dt, where M(a, b, x) is the confluent hyperge-
ometric function of the first kind [48]. The exponential growth or decline then
becomes a special case of U (b, x) when b = 1, x , 0,
U (1, x) = xex
Z ¥
1
e t
t
dt = xexE1(x), (3.12)
where E1(x) is the Exponential Integral [48], which has been shown by previous
studies [8, 110]. We could not find feasible and numerically stable closed-form
formulas for fkj when the population size decreases forward in time in a manner
that is not linear or exponential (i.e. rk < 0 and bk < f0, 1g). In these scenarios,
we used Gauss-Legendre quadrature [66] for efficient numerical evaluation of
relevant functions (see Appendix A.6 for detailed description).
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3.3.4 Software Implementation
The above expressions are implemented in a software package, EGGS (Efficient
computation of Generalized models’ Genetic summary Statistics). The source
code and compiled programs for Linux and Mac OS platforms are publicly
available from website http://keinanlab.cb.bscb.cornell.edu. Source code was
written in C++, with no external libraries needed for compilation. Additional
information of implementation is included in Appendix A.7 and in the manual
that accompanies the software online.
3.3.5 Demographic Models Assumed in This Study
The demographic models used in this study are based on the inferred European
history presented by [44] (Figure 3.2, in black), which contains two bottlenecks
[68] and a recent exponential growth epoch. Specifically, model presented in
[44] inferred that European population had a constant effective population size
of 10,000 (diploid) individuals before 4,720 generations ago, and went through
the ancient bottleneck between 4,720 and 4,620 generations ago with a popula-
tion size of 189. The population size then recovered to 10,000 diploids until 720
generations ago, from which time the recent bottleneck started with a size of
549. At 620 generations ago, the population size recovered to 5,633 individuals.
The recent growth epoch started from 140.8 generations ago and led to a pop-
ulation size of 654,000 at present. The parameters of the original recent growth
epoch were varied to incorporate generalized growth effects.
In addition to using the model mentioned above, we also applied an alter-
native model of ancient European history for inference. The model was first
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Figure 3.2: Comparison of four summary statistics estimated by FTEC simu-
lation and computed by EGGS. (A) Demonstration of the demographic mod-
els considered for evaluating the accuracy of our calculations as implemented
in EGGS. This two-bottleneck model has the same population size and time
throughout history as in the inferred European history in [44], with the excep-
tion that we varied the growth speed parameter of the recent growth epoch to
be b = 0.5 (sub-exponential, blue), b = 1.0 (exponential, black) and b = 1.5
(super-exponential, red). The y-axis shows effective population size of diploid
individuals on log scale. (B)-(E) The comparison of the first 15 entries of the SFS
(B), the total number of segregating sites (S) across all 200,000 loci (1,000 bp-long
each) (C), the expected pairwise difference between chromosomes per base pair
(D) and the burden of private mutation (a) as the percentage of heterozygous
variants in one individual that are monomorphic in the rest of the sample of
999 individuals (E) computed numerically in EGGS (dark bars) and simulated
by FTEC (light bars) for the demographic models shown in (A): b = 0.5, blue;
b = 1.0, black; b = 1.5, red, with a sample size of 1,000 individuals (2,000 chro-
mosomes). The y-axis in (B) is on log scale.
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presented in [49] and later used in [127]. This model inferred that European
population had an ancient effective population size of 7,300 diploid individu-
als until 6,167 generations ago, when the population size expanded to 14,474
individuals. The first bottleneck took place 2,125 generations ago, with the pop-
ulation size reducing to 1,861 individuals. This first bottleneck lasted until 958
generations ago, at which time a second bottleneck took place with a decreased
population size of 1,032. We assumed 24 years per generation [120] to translate
the year-based time presented in the original model. For compatibility with the
model in [44], we considered that the population size had an instantaneous re-
covery after the second bottleneck lasted for 100 generations, instead of gradual
recovery [44]. Figure A.2 shows the schematic representation of the model in
[49].
3.3.6 Demographic Inference Framework Based on the Site Fre-
quency Spectrum
Demographic inference in this studywas based on the observed allele frequency
counts from the simulated or real dataset. To determine the fitness of a model
N(T) to the observed data, we calculated the composite log likelihood by
L[N] = logE [ jN] = C E [ jN], (3.13)
where C is a vector of the observed folded allele frequency counts and E [ jN]
is the computed folded SFS under demographic model N(T). More detailed
description can be found in Appendix A.11.
To search for the maximum likelihood point over the parameter space, we
applied the ECMmethod [101], which was previously used in the demographic
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inference study by [37]. 100 ECM cycles were performed for each run of infer-
ence. We obtained 95% confidence intervals of parameter estimates via block
bootstrapping of the data 200 times. Specifically, if the original data contains l
loci, we randomly chose l loci from the original data with replacement in each
bootstrap (see Appendix A.9 for details).
3.3.7 Processing of NHLBI Exome Sequencing Project Data for
Demographic History Inference
The NHLBI Exome Sequencing Project (ESP) dataset [41, 127] contains deep se-
quencing of 4,300 individuals of European ancestry. An important feature of
these data is the high sequencing coverage, which allows capturing very rare
variants accurately. These variants constitutes the part of the SFS that is most
enriched for information on recent population growth [42, 67, 127]. To reduce
the effect of selection as much as possible while keeping sufficient amount of
data, we chose to use the SFS calculated from synonymous single nucleotide
variants (SNVs) only, as previously performed by [127]. To further improve the
quality of the data, we filtered SNVs with average read depth less than or equal
to 20, or with successful genotype counts smaller than 7,740 (90%), and subsam-
pled the remaining 233,134 SNVs to 7,740 alleles, which is equivalent to 3,870
diploid individuals (Appendix A.10).
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3.4 Results
3.4.1 Comparison with Simulated Results by FTEC
To validate that the expressions provided in the Methods and Materials sec-
tion can correctly compute the summary statistics under generalized growth
models, we compared the summary statistics calculated by our software EGGS
to those simulated by the software FTEC (a coalescent simulator for modeling
faster than exponential growth by [117]) under the demographic models shown
in Figure 3.2(A). This model is the inferred European history in [44], except that
we varied the growth speed parameter b (Equation (3.1)), which corresponds to
1 in the original model (exponential growth), to also be 0.5 (corresponding to
sub-exponential growth) and 1.5 (corresponding to super-exponential growth).
The sample size is fixed at 1,000 diploid individuals (2,000 chromosomes). For
FTEC simulation, we used a mutation rate of 1.2 10 8 per base pair per gen-
eration (e.g., [75]) and simulated 200,000 independent loci, each of 1,000 base
pairs.
The comparison of the SFS, S (across all 200,000 loci), p and a numerically
computed by EGGS to that simulated by FTEC is shown in Figure 3.2(B)-(E). For
each demographic model illustrated in Figure 2(A), the values for all summary
statistics from the numerical computation by EGGS are practically identical to
those from the simulation results by FTEC. However, our software EGGS ex-
hibits a huge speed improvement over FTEC. For each model considered in Fig-
ure 3.2(A), EGGS takes less than a second to generate the results, while it takes
about 5 hours for FTEC to simulate the sequences, due to the large number of in-
dependent loci required for accurate estimation (performed in Ubuntu system
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with Intel Xeon CPU @ 2.67GHz). For instance, when 2,000 independent loci
are simulated, which still takes about 3 minutes, the summary statistics deviate
considerably from the accurate results (Figure 3.3 and Table 3.1). Furthermore,
our software works well over a wide range of values of the growth parameter
b, even when b = 0 (corresponding to linear growth or decline) or b < 0 (Fig-
ure 3.4), conditions that are not handled by FTEC. We note, however, that as a
simulation program FTEC provides the full sequences as output and can have
a wider range of applications than facilitated by the SFS and other summary
statistics that EGGS calculates.
Figure 3.3: Comparison of the first 15 entries of the SFS computed numerically
in EGGS and simulated result by FTEC (light bars). Only 2,000 loci (1,000
bp-long each) instead of 200,000 were simulated for the demographic models
shown in Figure 3.2(A): b = 0.5, blue; b = 1.0, black; b = 1.5, red. y-axis is on
log scale.
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Figure 3.4: Expected values of summary statistics generated under demo-
graphicmodels with awide range of the growth speed parameter (b). The time
values and population size values are kept the same as shown in Figure 3.2(A).
The growth speed parameter (b) of the recent epoch takes values from  15 to
15. The sample size is 10,000 individuals. The mutation rate per site per gener-
ation m0 = 1.2 10 8. We assumed a total of 2 108 sites, thus the locus-based
mutation rate m = 2.4. (A) The demonstration of the demographic models for
several values of b. To better exhibit the difference between different values of
b, only the most recent 400 generations are shown. The two dotted purple lines
show the constant-size model fixed at 5,633 (corresponding to b ! ¥) and an
instant-increase model with a sudden change from 5,633 to 654,000 at 140.8 gen-
erations ago (corresponding to b !  ¥). (B)-(E) The expected value of TMRCA,
S, a at n = 9,999 and p respectively for b varying from  15 to 15. The two dot-
ted purple lines correspond to the expected values for the scenarios shown by
the dotted purple lines in (A). (F) The expected proportion of singletons (red),
doubletons (blue) and the sum of the rest entries of the SFS for b varying from
 15 to 15. The dotted lines show expected singletons (red), doubletons (blue)
and the rest (black) of the SFS for the scenarios shown by the dotted purple lines
in (A).
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Table 3.1: Comparison of summary statistics computed by EGGS and esti-
mated by FTEC simulation. Only 2,000 loci (1,000 bp-long each) were simu-
lated for the demographic models shown in Figure 3.2(A). Presented are (i) the
total number of segregating sites (S) across all 2,000 loci (1,000 bp-long each),
(ii) the mean pairwise difference between chromosomes per base pair (p), and
(iii) the burden of private mutation (a) as the percentage of heterozygous vari-
ants in one individual that are monomorphic in the rest of the sample of 999
individuals.
Values of b
0.5 1.0 1.5
S(10 4) EGGS 10.06 9.70 7.72FTEC 10.06 8.96 7.73
p(10 4) EGGS 3.58 3.57 3.57FTEC 3.53 3.49 3.56
a(10 3) EGGS 7.56 5.97 4.18FTEC 7.66 6.00 4.24
3.4.2 Evaluating Inference of GeneralizedGrowth Based on the
Site Frequency Spectrum
We next set out to test the accuracy (as a function of sample size) of inferring pa-
rameters in models with generalized growth from the SFS. It has been shown in
[7] that in theory, an underlying generalized growth demographic model can be
uniquely identified by the ideal, perfect expected SFS with a very small sample
size generated from that model (34 haploid sequences for the models shown in
Figure 3.2(A)). However, the SFS is estimated in practice from a limited amount
of data from each individual (even in the case of whole-genome sequencing) and
as a result, the estimated SFS will fluctuate around the expected values, which
limits its accuracy for inference [128]. We aim to test such inference in practice
and determine the power of generalized growth detection and the sample size
needed for accurately recovering the growth parameter and other parameters
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of the demographic model. To be comparable with many practical applications,
we considered sequence length that is about equivalent to that obtained from
whole exome sequencing (Appendix A.9).
We performed inference on the SFS calculated from simulated sequences
generated by FTEC. We simulated a demographic model with the same initial
epochs as the model illustrated in Figure 3.2(A). Starting 620 generations ago,
the simulatedmodel included a constant population size of 10,000 until 200 gen-
erations ago, when the population starts a generalized growth epoch till present.
The generalized growth epoch starts with a population size of 10,000 that grows
to an extant effective population size of 1 million individuals, with the growth
speed parameter b taking each of the following values: 0.4, 0.7, 0.9, 1.0, 1.1, 1.3
and 1.6. We chose these values to represent a range of super-exponential and
sub-exponential growth, with emphasis on values around the exponential rate
(b = 1.0) in order to test the detection power of generalized growth when the
growth speed deviates slightly from exponential. We varied the sample size
(number of diploid individuals sampled at present) to be 1,000, 2,000, 3,000,
5,000 and 10,000. The first 15 entries of the site frequency spectra for these sim-
ulated scenarios are shown in Figure 3.5. From each set of simulations, we then
infer four parameters of the recent growth epoch, which can uniquely determine
the epoch: 1) the growth speed parameter b; 2) the initial population size before
growth Nf; 3) the ending population size after growth Ni; and 4) the onset time
of growth T, which is equivalent to the growth duration since the simulated
epoch ends at present.
As sample size increases, the accuracy of the point estimates generally im-
proves and the confidence interval narrows (Figure 3.6). Specifically, when the
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Figure 3.5: The first 15 entries of the site frequency spectra for different sim-
ulation scenarios. (A)-(G): corresponding to b = 0.4, b = 0.7, b = 0.9, b = 1.0,
b = 1.1, b = 1.3 and b = 1.6 respectively for the recent generalized growth
epoch, with sample size of 1,000 diploids (blue), 2,000 diploids (red), 3,000
diploids (green), 5,000 diploids (orange) and 10,000 diploids (cyan).
SFS of only 1,000 diploids is used for inference, the inference performs badly
for all parameters with large confidence intervals (Figure 3.6). However, the
confidence interval always includes the true simulated value. A sample size of
2,000 already exhibits acceptable performance except when the growth speed
becomes large (b = 1.3 and 1.6). Larger sample sizes of 5,000 and 10,000
are sufficient for inferring all parameters with very tight confidence intervals.
For such sample sizes, the inference even significantly distinguishes between
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growth speeds (b = 0.9 and b = 1.1) that are close to exponential (b = 1.0)
from that of an exponential, thereby concluding that a sub-exponential (0.9) or
super-exponential (1.1) growth has taken place. These observations suggest that
a sample size of at least 3,000 diploid individuals might be needed for inferring
the parameters associated with the simulated recent generalized growth epoch,
which is motivated by previous models of European demographic history. It
remains to be explored how accurate the estimates are, and how their accuracy
improves with sample size, across a more diverse set of models.
3.4.3 European Demographic History Inference
We next performed demographic inference on NHLBI Exome Sequencing
Project (ESP) data [41, 127]. We applied our inference to these data while consid-
ering and comparing two models. Both models assume the ancient epochs be-
fore 620 generations ago to be the same as those in the model by [44] illustrated
in Figure 3.2(A). We inferred the parameters only for the most recent epoch,
which is of generalized growth in one model while limited to exponential growth
in the other. The parameters for inference were: for both models (1) population
size before growth (Nf), (2) population size after growth (Ni), (3) growth onset
time (T), which is equivalent to the duration of growth; only for the generalized
growth model (4) the growth speed parameter (b), which is fixed at b = 1 for the
exponential growth model. The point estimates and 95% confidence intervals are
shown in Table 3.2 and the best-fit demographic models are illustrated in Figure
3.7(AB) (also see Figure A.3, A.4 and A.5).
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Figure 3.6: Inference results on simulated data with a recent generalized
growth epoch. The model parameters are as follows: Growth starts 200 gener-
ations before present from an effective population size of 10,000 and ends with
an effective population size of 1 million at present. The growth speed param-
eter b takes the following values in different simulations: 0.4, 0.7, 0.9, 1.0, 1.1,
1.3, and 1.6. Inference of these four parameters is based on the SFS estimated
from a sample of individuals of one of five sizes (1,000, black; 2,000, red; 3,000,
blue; 5,000, brown; and 10,000, green). The point estimates with 95% confidence
interval for these parameters are grouped by the growth speed parameter b (x-
axis). The dashed purple lines show the true values of the simulatedmodel. The
results are shown in the following order: (A) the inferred growth speed param-
eter, (B) the inferred population size before growth, (C) the inferred population
size after growth, (D) the inferred growth start time. The y-axis in (C) is on log
scale.
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Figure 3.7: Demographic inference results based on ESP data. (A) Illustration
of the effective population size (y-axis, on log scale) over time for the best-fit
models inferred based on ESP data assuming the ancient history is the same as
that in [44]. Two models are shown: One restricted to recent growth being ex-
ponential (black) and one with a generalized recent growth epoch (red). Before
620 generations ago, the model was not inferred and all parameters were set
to be the same as those shown in Figure 3.2(A). Solid lines show the effective
population size over time of each of the inferred models, with dashed line indi-
cating estimated parameter values on the x-axis or y-axis. Only the most recent
1,000 generations are shown to emphasize the difference between the two mod-
els. (B) A zoom-in to the most recent 240 generations of the inferred models
in (A) to emphasize the acceleration pattern of the generalized growth model,
with y-axis on linear scale. (C) Similar to panel (A), except that the best-fit mod-
els presented are based on the assumption that the ancient history before 858
generations ago is fixed to that in [49] (see Figure A.2). (D) A zoom-in to the
most recent 240 generations of the inferred models in (C).
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Table 3.2: Demographic inference results using ESP data for a model with
a recent epoch of exponential growth and a model with a recent epoch of
generalized growth. Shown are point estimates and 95% confident intervals (in
parenthesis) for the following parameters of the inferred recent growth epoch
when the ancient history was assumed to be the same as that in Gazave et al.
(2014) model and Gravel et al. (2011) model: population size before growth
(Nf), population size after growth (Ni), time growth started in generations (T),
and the growth speed parameter (b), which is fixed at b = 1 in the exponential
growth case.
Ancient
History Growth Model Nf (10
4) Ni (106) T b
Gazave
Model
Exponential 1.31(1.26-1.36)
1.04
(1.00-1.07)
198
(195-202) N/A
Generalized 1.24(1.18-1.30)
1.26
(1.16-1.37)
213
(206-220)
1.12
(1.07-1.15)
Gravel
Model
Exponential 0.89(0.86-0.93)
0.85
(0.82-0.88)
186
(182-190) N/A
Generalized 0.78(0.74-0.83)
1.33
(1.22-1.46)
218
(211-228)
1.22
(1.18-1.26)
Although the model by [44] assumed a different ancient history before the
recent growth epoch than that assumed in [127], using ESP data and assuming
exponential growth, the inferred growth epoch is generally consistent with that
obtained in their study (Figure 3.7(AB) and Table 3.2). Our study infers that re-
cent growth started 198 (95% CI: 195-202) generations ago with an effective pop-
ulation size of 13,100 (12,600-13,600) and continued at a rate of 2.2% (2.15%-
2.26%) per generation (Table 3.2), while [127] estimated that recent growth had
an initial population size of 9,500 individuals, a duration of 204 generations
and a growth rate of 2.0% per generation.
The inferred generalized growth model fits the data significantly better than
that with exponential growth (P-value = 3.85 10 6 by c2 likelihood-ratio test
with 1 degree of freedom). It estimates that growth started 213 (206-220) genera-
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tions ago from an effective population size of 12,400 (11,800-13,000), both values
consistent with those estimated in the exponential growth model. The extant ef-
fective population size following growth is estimated to be 1.26 (1.16-1.37) mil-
lion. The inferred growth speed parameter b = 1.12 (1.07-1.15) is significantly
larger than exponential speed of b = 1 (P-value  10 12 using one-tailed z-
test), which is the main difference between the two models. b = 1.12 implies
a growth rate acceleration pattern that is super-exponential at 12% faster than
exponential through the epoch (Figure 3.7): the super-exponential growth is rel-
atively slow around the onset time, and it keeps accelerating as time approaches
present.
To test the sensitivity of the model to the assumption of ancient European
history, we considered an alternate model of ancient history. We fixed the his-
tory before 858 generation ago to be that inferred by [49] for Europeans (Sec-
tion 3.3). We repeated inference of the same parameters using the same ESP
data. The inferred parameters for exponential growth are also similar to those
obtained in [127] that were based on the model by [49] (Table 3.2). However,
the SFS from this model fits the data worse than that from the exponentialmodel
based on the ancient history of the model by [44] (p-value = 1.59 10 6 from
c2 goodness of fit test between exponential Gravel model and ESP data, which is
0.97 for exponential Gazave model; see Appendix A.12 and Table 3.3). By apply-
ing a generalized growth epoch to the model by [49], the inferred parameters are
generally in line with those from generalized Gazave model, although some dif-
ferences exist (Table 3.2), indicating that the assumption of ancient history can
affect the inference of recent growth to some extent. More importantly, general-
ized Gravel model fits the data almost equally well as generalized Gazave model,
which is significantly better than the exponential model (p-value  10 12 by
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c2 likelihood-ratio test; also see Table 3.3). As with generalized Gazave model,
the inferred growth speed parameter from generalized Gravel model, b = 1.22
(1.18-1.26), is also significantly larger than the exponential speed b = 1 (P-value
 10 12 using one-tailed z-test; Figure 3.7(CD)).
Table 3.3: Goodness of fit between the SFS from inferred models and ESP
data. We show the p-value from c2 goodness of fit test and KL divergence be-
tween the SFS from the ESP data and that from the constant population size
model, the inferred exponential model, the generalized model and the two-
epoch exponential model. The assumed ancient history (Gazave model or
Gravel model) is indicated in parenthesis. The constant population size model
is included here for comparison purposes.
Model p-value from c2 test KL divergence
Constant 0 0.84
Exponential (Gazave) 0.97 1.64 10 4
Generalized (Gazave) 1 1.15 10 4
Two-Epoch Exponential (Gazave) 1 1.09 10 4
Exponential (Gravel) 1.59 10 6 4.12 10 4
Generalized (Gravel) 1 1.15 10 4
Motivated by these results, we considered a third model with two recent
exponential growth epochs, which still assumes the ancient epochs before 620
generations ago to be the same as those in the model by [44] illustrated in Fig-
ure 3.2(A). Five parameters were inferred (Table 3.4), with the first phase of
growth estimated to start 219 (95-334) generations ago with a population size
of 12,200 (11,700-13,200). This phase of growth lasts until 135 (25-157) gener-
ations ago and leads to a population size of 47,100 (30,200-540,900). The pop-
ulation size after the recent phase of growth is 1.12 (1.07-2.09) million. This
model provides a significantly better fit than the model with a single exponen-
tial growth (P-value = 5.55  10 6 by c2 likelihood-ratio test with 2 degrees
of freedom), but is a worse model than the generalized growth model (based on
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Bayesian Information Criterion, BICtwo epoch exponential   BICgeneralized = 6.1).
However, this model exhibits some of the same accelerating pattern as in the
generalized growth model, ascertained by the growth rate of the most recent ex-
ponential epoch being 2.4% (2.3%-5.2%), larger than that of the first exponential
epoch, 1.6% (1.3%-2.1%). This acceleration pattern shown in both the general-
ized model and the model with two exponential epochs is consistent with evi-
dence of growth in European census population size that has greatly accelerated
in Modern Era [67].
Table 3.4: Demographic inference results using ESP data for a model with
two recent epochs of exponential growth. Shown are point estimates and 95%
confident intervals (in parenthesis) for the following parameters of the inferred
epoch: population size before growth (N2), population size after the more an-
cient phase of exponential growth (N1), population size after the recent phase
of exponential growth (N0), time when the ancient phase of exponential growth
started (T2, in generations), time when the recent phase of exponential growth
started (T1, in generations).
N2(104) N1(104) N0(106) T2 T1
1.22 4.71 1.12 219 135
(1.17  1.32) (3.03  54.09) (1.07  2.09) (95  334) (25  157)
3.5 Discussion
In this study, we provide the mathematical derivation and a software that can
efficiently compute the expected values of five genetic data summary statistics
given a generalized demographic model by evaluating the derived explicit ex-
pressions. These summary statistics include the time to themost recent common
ancestor (TMRCA), the total number of segregating sites (S), the site frequency
spectrum (SFS), the average pairwise difference between chromosomes per site
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(p) and the burden of private mutation (a). The fast and accurate generation of
these summary statistics under generalized models can provide a useful tool in
the studies of human demographic inference. For instance, in addition to infer-
ence based on the SFS as in the present study, a recent study [22] presented an
inference framework based on the total number of segregating sites. The results
in this study can be easily incorporated into that framework. Furthermore, the
source code of the software is freely available to allow extensions to compute
other summary statistics of interest (for example, the joint-SFS of samples from
multiple populations under generalized models by extending [21] and [137]).
Such extensions can facilitate a variety of population genetic studies in humans
and other organisms beyond the inference of demographic history.
It is also possible that other families of growth models may fit the pattern of
human population size history. For instance, a recent study [34] considered the
algebraic-growth model in the form of N(T) = Tg. In reality, however, not all
demographic models have numerically stable closed-form expressions for the
expected time of the first coalescent event (yj). In these cases, fast and accu-
rate numerical integration methods, such as Gauss-Legendre quadrature used
in this work, can be applied to evaluate yj. This technique holds the promise of
efficiently generating the expected value of population genetic summary statis-
tics under arbitrary population size functions.
It has been pointed out that as sample size increases, the assumptions of
standard Kingman’s coalescent are violated as multi-merger and simultaneous-
merger events can become non-negligible [6]. Such events can distort the ge-
nealogies and potentially cause the values of summary statistics to be different
from those under Kingman’s coalescent [6]. To explore such discrepancies, we
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compared the SFS from Kingman’s coalescent and discrete-time Wright-Fisher
(DTWF)model [6] under the inferred demographic history in generalizedGazave
model with a sample size of 3,870 diploids (Appendix A.13). We observed that
the SFS from DTWF model and Kingman’s coalescent are very similar (Figure
3.8), which means that multi-merger and simultaneous-merger events should
not have a significant effect on the inference carried out in this study. How-
ever, it remains valuable to systematically study the effect of multi-merger and
simultaneous-merger events in the context of generalize growth, especially as
sample size increases.
By applying inference of generalized growth on the SFS generated from the
synonymous variants of 4,300 individuals of NHLBI ESP dataset [41, 127], we
found that generalized growth model shows a better fit to the observed data than
the exponential growth model that has been used by all previous demographic
modeling studies (P-value= 3.85 10 6). We also find that the European popu-
lation experiences a recent growth in population size with speedmodestly faster
than exponential (b = 1.12, P-value  10 12 for difference from b = 1). This
result is consistent with previous speculations that human population might
have undergone a recent accelerated growth epoch based on the observation
of very rare, previously unknown variants in several sequencing studies with
large sample sizes [41, 108, 127]. It is also in line with the super-exponential
growth in census population size during that time [67]. In future studies, it will
be valuable to incorporate gradient-based optimization techniques for the fast
inference of demographic models containing generalized growth epochs, e.g.,
by extending the work of [8]. Such improvement will enable simultaneous in-
ference of recent growth and more ancient epochs.
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Figure 3.8: Effects of multi-merger and simultaneous-merger events on the
SFS. The underlying demographic model is the best-fit generalized model us-
ing the ancient history in Gazave et al. (2014). The sample size is 3,870 diploid
individuals. (A) The 100-entry partially normalized SFS under Kingman’s coa-
lescent and under discrete-timeWright-Fisher model. (B) The percentage differ-
ence of entry-to-singleton ratio between Kingman’s coalescent and discrete-time
Wright-Fisher model for the first 100 entries.
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To minimize the impact of natural selection on our demographic inference,
we considered only synonymous SNVs for demographic modeling, as in the
original study [127]. However, it is still a potential limitation that the data is
affected by negative and background selection. Hence, it remains valuable to
validate the result of super-exponential growth by conducting inference on SFS
calculated from more neutral genomic regions [44] or by modeling the effect of
selection. One promising possibility is extracting genomic regions that are less
subject to selection from whole genome sequences in the UK10K project [126].
More generally, with the increasing availability of high-quality whole-genome
sequencing data with large sample sizes for humans and other species, more
refined and realistic demographic models can be estimated with generalized
growth models.
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CHAPTER 4
NEWMETHODS FOR ANALYZING THE X-CHROMOSOME IN
ASSOCIATION STUDIES WITH SOFTWARE IMPLEMENTATION AND
APPLICATIONS
4.1 Abstract
XWAS is a new software suite for the analysis of the X chromosome in associa-
tion studies and similar genetic studies. The X chromosome plays an important
role in human disease and traits of many species, especially those with sexu-
ally dimorphic characteristics. Special attention needs to be given to its analysis
due to the unique inheritance pattern, which leads to analytical complications
that have resulted in the majority of genome-wide association studies (GWAS)
either not considering X or mishandling it with toolsets that had been designed
for non-sex chromosomes. We hence developed XWAS to fill the need for tools
that are specially designed for analysis of X. Following extensive, stringent, and
X-specific quality control, XWAS offers an array of statistical tests of associa-
tion, including: 1) the standard test between a SNP (single nucleotide polymor-
phism) and disease risk, including after first stratifying individuals by sex, 2) a
test for a differential effect of a SNP on disease between males and females, 3)
motivated by X-inactivation, a test for higher variance of a trait in heterozygous
females as compared with homozygous females, and 4) for all tests, a version
that allows for combining evidence from all SNPs across a gene. We applied the
toolset analysis pipeline to 16 GWAS datasets of immune-related disorders and
7 risk factors of coronary artery disease, and discovered several new X-linked
genetic associations. XWAS will provide the tools and incentive for others to
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incorporate the X chromosome into GWAS and similar studies in any species
with an XX/XY system, hence enabling discoveries of novel loci implicated in
many diseases and in their sexual dimorphism.
4.2 Introduction
Genome-wide association studies (GWAS) have identified thousands of loci un-
derlying complex human diseases and other complex traits [138]. While suc-
cessful for the autosomes (nonsex chromosomes), the vast majority of these
studies have either incorrectly analyzed or ignored the X chromosome (X) [142].
In most studies, all variants on the X have been removed as a consequence of
the quality control (QC) procedures [18, 97, 132, 142]. Many other studies that
did analyze the X chromosome incorrectly applied methods that have been de-
signed for the autosomes, without accounting for the analytical problems aris-
ing from X’s unique mode of inheritance and its consequent population genetic
and evolutionary patterns [4, 35, 51, 52, 70, 80, 89, 141]. As a result, the role X
plays in complex diseases and traits remains largely unknown.
Many human diseases commonly studied in GWAS show sexual dimor-
phism, including autoimmune diseases [136], cardiovascular diseases [81] and
cancer [100, 106], which suggests a potential contribution of the X chromosome
[17, 109]. Several recent studies have examined this issue and demonstrated
the potential value of analyzing X [18, 46, 84, 94, 133]. However, while associa-
tion methods, QC and analysis pipelines are well established for the autosomes,
respective pipelines for X-linked data are not readily available. Hence, in this
article, we introduce the software package XWAS (chromosome X-Wide Anal-
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ysis toolSet), which is tailored for analysis of genetic variation on X in human
and other species with an XX/XY system. It implements extensive functionality
that carries out QC specially designed for the X chromosome, statistical tests of
single-marker association that account for its unique mode of inheritance, gene-
based tests of association, and additional distinct tests only applicable to X that
capitalize on its mode of inheritance. In implementing these features, the toolset
builds on–and complements–the commonly used PLINK [113] software. It in-
cludes many novel features that can facilitate X-wide association studies that
are not available in PLINK and, to the best of our knowledge, in any other soft-
ware. Combined, the XWAS toolset integrates the X chromosome into GWAS as
well as into the next generation of sequence-based association studies and into
studies of other species.
4.3 Features and Functionality
4.3.1 Quality Control Procedures
The XWAS toolset implements a whole pipeline for performing QC on geno-
type data for the X chromosome. The pipeline first follows standard GWAS QC
steps as implemented in PLINK [113] and SMARTPCA [112] by running these
tools. These include the removal of both individual samples and SNPs (single
nucleotide polymorphisms) according to multiple criteria. Specifically, samples
are removed based on 1) relatedness, 2) high genotype missingness rate, and
3) genetic ancestry differing from the majority of the samples [112]. SNPs are
removed based on criteria such as their missingness rate, their minor allele fre-
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quency (MAF), and deviation from Hardy-Weinberg equilibrium (HWE). This
entire QC pipeline is applicable to both case-control GWAS (binary traits) and
GWAS of quantitative traits. One filter applied only to binary traits is the re-
moval of SNPs for which missingness is correlated with the trait, that is, with
case or control status (--test-missing).
To consider differences in genotyping between hemizygous males and
diploid females, XWAS applies all the aforementioned QC steps of samples sep-
arately for males and females. Consequently, a unified dataset is generated for
subsequent analyses that include all SNPs and individuals passing the above
filtering criteria in both the male and female QC groups.
The pipeline then applies X-specific QC steps, which are exclusively built
into XWAS, to the unified dataset. These include 1) removing SNPs with signif-
icantly different MAF between male and female samples in the control group
(--freqdiff-x), 2) removing SNPs with significantly different missingness rates be-
tween male and female controls (--missdiff-x), and 3) the removal of SNPs in the
pseudoautosomal regions (PARs). The first 2 of these steps capture problems in
genotype calling when plates include both males and females [76].
4.3.2 Single-Marker Association Testing on the X Chromosome
For an X-linked SNP, while females have 0, 1, or 2 copies of an allele, hemizy-
gous males have at most one copy. Via the process of X-inactivation, 1 of the 2
copies in females is usually transcriptionally silenced. If X-inactivation is com-
plete, it produces monoallelic expression of X-linked protein-coding genes in fe-
males. Therefore, when considering loci that undergo complete X-inactivation,
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it may be apt to consider males as having 0/2 alleles, corresponding to the fe-
male homozygotes (the FM02 test). The toolset carries out this test for associa-
tion between a SNP and disease risk by using the --xchr-model 2 option in PLINK
[113]. For other scenarios though, including where some genes on the X escape
X-inactivation or different genes are inactivated in different cells, it can be more
indicative to code males as having 0/1 alleles. Hence, the toolset further carries
out such an association test (FM01 test) of a SNP by using the following options
in PLINK : --logistic and --linear for binary and quantitative traits, respectively.
All tests, including tests described in following sections, allow for covariates
such as population structure, sex, and traits that are correlated with the disease,
as commonly considered in GWAS. We suggest calculating principal compo-
nents by using EIGENSTRAT [112] and include them as covariates to control
for population structure. Ten such principal components are considered by de-
fault, unless otherwise specified. Any other user-defined covariates can also be
incorporated.
4.3.3 Single-Marker Sex-Stratified Analysis on the X Chromo-
some
The XWAS software further includes new tests that are not included in PLINK.
First, we implemented a new sex-stratified test, FMcomb, which is particularly
relevant for X analyses since SNPs and loci on the sex chromosomes are po-
tentially more likely to exhibit different effects on disease risk between males
and females. In such scenarios, as well as in scenarios where the effect is only
observed in one sex, a sex-stratified test as described in the following can be
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better powered. This functionality is accessible by the option --strat-sex. The
FMcomb test first carries out an association test separately in males and females
and then combines the results of the 2 tests to obtain a final sex-stratified sig-
nificance level. The combination of the 2 test statistics is implemented using
both Fisher’s method (--fishers) [39] (in the FMF.comb test) and Stouffer’s method
(--stouffers) [123] (in the FMS.comb test).
Each of these 2 tests is more powerful in different scenarios [18], for example,
FMF.comb allows the SNP tested to have different, even an opposite, effect on
disease risk in males and females. FMF.comb is also insensitive to whether males
are coded as 0/2 (as in the FM02 test) or as 0/1 (as in the FMS.comb test), thus
making no assumptions regarding X-inactivation status. Alternatively, FMS.comb
directly accounts for the potentially differing sample sizes between males and
females to maximize power. For this latter test, XWAS weighs by the sample
size in males and females in cases and controls following the approach of [139].
4.3.4 Single-Marker Sex-Differentiated Effect Size Test on the
X Chromosome
We described above sex-stratified tests that accommodate associations with dif-
ferent effect size between males in females. In another type of test (FMdiff), we
directly test whether the effect size is different between the sexes. This test, ap-
plied to each SNP, runs a t-test [116] to test for difference between the odds ratio
(OR) in males alone and the OR in females alone for case-control studies,
t =
logORmale   logORfemaleq
se2male + se
2
female   2r  semale  sefemale
(4.1)
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or to test for difference the male-specific and female-specific b estimates for
quantitative traits,
t =
bmale   bfemaleq
se2male + se
2
female   2r  semale  sefemale
(4.2)
while accounting for hemizygosity in males. This test is implemented under
the --sex-diff option. For this test and the sex-stratified test, both odds ratios
and regression coefficients in each sex can be provided as output for further
examination.
4.3.5 Single-Marker Variance-Based Testing Informed by X-
Inactivation in Females
The details of this variance-based test are described in [84]. The major work of this test
was done by the authors of that paper.
During X-inactivation, the expression of one copy of the X chromosome in fe-
males is randomly silenced, thereby increasing variation in the expression of X-
linked quantitative trait loci (QTL). Specifically, females that are heterozygotes
for a QTL might exhibit higher phenotypic variance than homozygous females
since one or the other allele might be more dominantly affecting the phenotype
in each given female heterozygote, such that for some individuals the QTL ex-
pression is more similar to one type of female homozygous, while to the other
type in other individuals. We developed a test aimed at capturing this increased
variance as a means for detecting X-linked QTLs in females. This test (Fvar) is
implemented under the --var-het option. Although this Fvar test is implemented
for quantitative traits, it can be generalized to qualitative traits by applying li-
ability threshold modeling [144] to transform disease status to an unobserved
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continuous liability.
The null hypothesis of the Fvar test is that phenotypic variances of the 3 geno-
typic groups of a SNP with 0, 1, or 2 copies of an allele are all equal. The
alternative hypothesis is that female heterozygotes show a higher phenotypic
variance than others. Hypothesis testing is carried out using a modified Brown-
Forsythe test of variances [15]. We first normalize the phenotypic value and
remove the effects of possible covariates by a linear regression as convention-
ally done, namely
y = m+ XB+ e, (4.3)
where y is a vector of quantitative trait levels, m is the population mean, X is the
matrix of possible covariates, and e is a vector of residuals. Assume yijg=j is the
phenotypic value of the ith individual in the jth genotypic group and zijg=j =
jeijg=jj is the absolute residual value of the ith individual in the jth genotypic
group (j = 0, 1, or 2 copies of an allele of a SNP). A test statistic is derived as
Tvar =
z¯1   z¯0/2r
s21
n1
+
s20/2
n0+n2
(4.4)
where z¯1 is the sample mean of zijg=1 over i, z¯0/2 is the sample mean of zijg=0
and zijg=2 combined, s21 and s
2
0/2 are the sample variances, respectively, and nj
is the sample size of the jth genotypic group. Under the null hypothesis, the
statistic follows a t-distribution with degrees of freedom given by
d f =

s21
n1
+
s20/2
n0+n2
2
(s21/n1)
2
n1 1 +
(s20/2/(n0+n2))
2
n0+n2 1
(4.5)
This variance-based test captures a novel signal of X-linked associations by di-
rectly testing for higher phenotypic variance in heterozygous females than ho-
mozygotes. As a test of variance it is generally less powerful than standard
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tests of association that consider means; however, it provides an independent
and complementary test to the standard association test for QTLs on X [94].
4.3.6 X-Linked Gene-Based Testing
XWAS also includes unique features for carrying out gene-based association
analysis on the X chromosome. Gene-based approaches may be better pow-
ered to discover associations than single-marker analyses in cases of a gene with
multiple causal variants of small effect size, or of multiple markers that are each
in incomplete linkage disequilibrium with underlying causal variant/s. Fur-
thermore, in studying the effect of X on sexual dimorphism in complex disease
susceptibility, it may be desirable to analyze whole-genes or all genes of a cer-
tain function combined based on their unique function or putatively differential
effect between males and females [18].
The XWAS package determines the significance of association between each
gene as a whole and disease risk by implementing a gene-level test statistic that
combines individual SNP-level test statistics for all SNPs in and around each
studied gene. This gene-level approach is applicable to any of the different tests
described above. For instance, beyond tests of association, it can be applied to
the sex-differentiated tests. In this case the gene-based test captures any sce-
nario whereby SNPs within the gene display different effects in males and fe-
males, without restricting such differential effects to be of a similar nature across
SNPs. By default, genes are considered from the UCSC browser “knownCanon-
ical” transcript ID track. SNPs are mapped to a gene if they are in the gene or
within 15kb of the gene’s start or end positions. The user can also provide a
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different set of gene definitions or alternate regions of interest and a different
window length around them in which SNPs are also to be considered.
Combining SNP statistics across a gene is implemented in the general frame-
work of [86]. Specifically, the significance of an observed gene-based test statis-
tic is assessed from the distribution of test statistics that is expected given the
linkage disequilibrium between the SNPs in the gene. In [86], the test statis-
tics for all SNPs in the gene are summed. Here, we have implemented a slight
modification to this procedure, wherebywe combined SNP-based P-values with
either the truncated tail strength [58] or the truncated product [145] method,
which have been suggested to be more powerful in some scenarios [93, 145].
To determine significance, XWAS follows the procedure in [86]. The ob-
served statistic is compared to gene-level test statistics obtainedwhen SNP-level
statistics are randomly drawn from amultivariate normal distributionwith a co-
variance determined by the empirical linkage disequilibrium between the SNPs
in the tested gene. The significance level is then the proportion, out of many
such drawings, for which this sampled gene-level statistic is more, or as extreme
compared with the empirical one. For computational efficiency, the number of
drawings is determined adaptively as in [86]. By combining the truncated tail
measures with this procedure, our new gene-based method combines the test
statistics from multiple SNPs that show relatively low P-values, while also ac-
counting for the dependency between these P-values due to linkage disequilib-
rium between the SNPs. Such a gene-based P-value is estimated for each gene
and for each of the X-linked tests described above.
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4.4 Implementation
The XWAS software package is implemented in C++ and includes in part func-
tions from open-source PLINK [113]. XWAS uses the same input format as
PLINK. Beyond C++, additional features are also implemented in scripts, in-
cluding in shell (for QC), Perl (for converting file formats and using SMART-
PCA), and R (for gene-based testing). The entire package is freely available for
download from http://keinanlab.cb.bscb.cornell.edu and includes 1) scripts, 2)
the binary executable XWAS, 3) all source code with a Makefile, 4) a user man-
ual, and 5) example data and examples of running the different options offered
by the package. Additional help is provided via the --xhelp option. The XWAS
toolset was initially designed and optimized for Linux systems, hence exhibits
best performance in such systems. A Makefile is also provided to facilitate local
compilation on Linux environments, and can also be adjusted for Windows and
MAC OS by revising a few lines indicated therein.
4.5 Applications
In this section, we summarize several sets of results obtained by applying the
XWAS software to several publicly available GWAS datasets. These results are
intended to demonstrate the usefulness of the XWAS software. More detailed
results are described in other papers [18, 94].
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4.5.1 Association of X-Linked SNPs with Autoimmune Dis-
eases
We applied the XWAS software to 16 GWAS datasets of autoimmune disease
and other disorders with a potential autoimmune-related component. These in-
clude the following datasets that we obtained from dbGaP (Mailman et al. 2007;
Tryka et al. 2014): ALS Finland [78] (phs000344), ALS Irish [30] (phs000127),
Celiac disease CIDR [3] (phs000274), MS Case Control (Baranzini et al. 2009)
(phs000171), Vitiligo GWAS1 [61] (phs000224), CD NIDDK [33] (phs000130),
CASP [107] (phs000019), and T2D GENEVA [114] (phs000091). Similarly, we ob-
tained the following datasets from theWellcome Trust Case Control Consortium
(WT): all WT1 (The Wellcome Trust Case Control Consortium 2007) datasets,
WT2 ankylosing spondylitis [36], WT2 ulcerative colitis [134] andWT2 multiple
sclerosis [57]. Finally, we also analyzed data from Vitiligo GWAS2 [60].
Following application of the QC pipeline as described above, we applied
the SNP-level FM02, FMF.comb, and FMS.comb tests to all SNPs in each of the 16
datasets. Based on the Vitiligo GWAS1 datasets, we associated SNPs in a region
17 kilobases (kb) away from the retrotransposed gene retro-HSPA8 with risk of
vitiligo. The parent of this retrotransposed gene, HSPA8 on chromosome 11,
encodes a member of the heat shock protein family, which has been previously
associated to vitiligo [1, 104, 105]. We discovered another association in WT2
ulcerative colitis of SNPs in an intron of BCOR contributing to ulcerative colitis
disease risk. BCOR indirectly mediates apoptosis via co-repression of BCL-6
[56].
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4.5.2 Association of Whole X-Linked Genes with Autoimmune
Diseases
We next focused on a gene-based analysis of the X chromosome by using the
SNP-level results of all the 3 tests in the above results as a basis for gene-based
tests in the same 16 datasets. This analysis led to the discovery of the first X-
linked gene-based associations with any disease or trait, which supports the
utility of the XWAS package in facilitating such analyses. We associated in Vi-
tiligo GWAS1 and replicated in Vitiligo GWAS2 an association between the gene
FOXP3 and vitiligo disease risk, in support of an earlier candidate gene study
[10]. We also found a novel association of ARHGEF6 to Crohn’s disease and
further replicated it in ulcerative colitis, another inflammatory bowel disorder
(IBD). ARHGEF6 binds to a surface protein of a gastric bacterium (Helicobacter
pylori) that has been associated to IBD [59, 91]. Finally, we associated CENPI
as contributing to the risk of 3 different diseases (amyotrophic lateral sclero-
sis, celiac disease, and vitiligo). Other, autosomal genes in the same family as
CENPI have previously been associated to amyotrophic lateral sclerosis [2] as
well as multiple sclerosis [5], supporting an involvement of CENPI with au-
toimmunity in general.
4.5.3 X-Linked SNPs Showing Sex-Differentiated Effect Size
with Autoimmune Disease
As a final analysis on the 16 autoimmune datasets, we applied the FMdiff test
and its gene-based version. Based on this test, we discovered and replicated the
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gene C1GALT1C1 (also known as Cosmc) as exhibiting sex-differentiated effect
size in risk of IBD. C1GALT1C1 is necessary for the synthesis of many O-glycan
proteins [65], which are components of antigens. We further found CENPI,
which we previously associated with several diseases, to show significantly dif-
ferent effects in males and females in the same diseases as in the association
analysis.
4.5.4 Increased Variance of Systolic Blood Pressure in Het-
erozygous Females for an X-Linked SNP
These results are described in [84] in detail. The major work was done by the authors of
that paper.
As an example application of the variance-based testing (Fvar) informed by X-
inactivation, we considered data on 7 quantitative traits from the Atheroscle-
rosis Risk in Communities (ARIC) study [140] along with Affymetrix 6.0 data
from the participating individuals, which included 34,527 X-linked SNPs. First,
we applied the entire set of QC procedures implemented in XWAS for quan-
titative traits. Then, we applied our single-marker variance-based testing and
compared with application of standard testing for a QTL. Across the 7 traits,
we found 1 SNP with a significant association based on the variance test [94].
Importantly, the signals of this test are not in the same loci as those of the stan-
dard test, in line with them capturing different types of signals. Specifically,
the significant SNP, rs4427330, which is associated with systolic blood pressure
based on the variance test, is not associated with any trait based on the standard
test. It is located upstream of AFF2, which might regulate ATRX. ATRX is as-
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sociated with alpha-thalassemia, a disease that can cause anemia and has been
associated with hypertension [11].
4.6 Conclusions
We have developed XWAS, an extensive toolset that facilitates the inclusion of
the X chromosome in GWAS. It offers X-specific QC procedures, a variety of X-
adapted tests of association, and an X-specific test of variance testing, available
for both single-marker and gene-based statistics. We applied this toolset to suc-
cessfully discover and replicate a number of genes with autoimmune disease
risk and blood pressure.
Additional changes and optimizations will be included in future versions of
this software. While imputation of unobserved SNPs is presently performed as
a preprocessing step using IMPUTE2 [54], we will incorporate X-specific impu-
tation as part of the pipeline. Additional features will include analysis of X-
linked data from sequence-based association studies (including burden tests),
statistical methods that have been previously designed for the X chromosome
[24, 25, 90, 130, 147], additional tests we previously proposed based on thework-
ings of X-inactivation [94], and tests for gene–gene interactions. Finally, we will
incorporate information regarding whether or how often a gene undergoes or
escapes X-inactivation [17, 28, 32]. For computational efficiency, we will also
continually upgrade the functions of PLINK that XWAS uses to the most recent
version.
This software, alone and through incorporation of additional features, can be
used for other types of studies of the X chromosome beyond association studies,
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in particular population genetic studies. For instance, allele frequency output
and testing for significant differences in allele frequency between males and
females as currently implemented, can be utilized to search for signals of selec-
tion.
Considering the availability of unutilized data for the X chromosome from
thousands of GWAS, and the additional X-linked data that is being generated
as part of ongoing GWAS, many researchers will find extensive utility in the
XWAS toolset. Furthermore, it is not limited to application to human data, but
rather genetic data from all organisms with XX/XY sex determination system,
including all mammals. XWAS will facilitate the proper analysis of these data,
incorporate X into GWAS and enable discoveries of novel X-linked loci as im-
plicated in many diseases and in their sexual dimorphism.
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APPENDIX A
APPENDIX FOR CHAPTER 3
A.1 Detailed description of genetic summary statistics
A.1.1 Total number of segregating sites (S)
Suppose we have n sequences (chromosomes), this quantity stands for the num-
ber of sites in which the sequences have different genotypes. Namely, if all
sequences have a common genotype for a site, this site is not considered as a
segregating site.
A.1.2 Time to the most recent common ancestor (TMRCA)
This statistic is the time taken for all of the samples at present to coalesce to the
same ancestor.
A.1.3 Site frequency spectrum (SFS)
Suppose we have n sequences sampled at present, the full SFS  has (n   1)
entries  = (x1, x2, . . . , xn 1), where xi records the fraction of segregating sites
that have i derived alleles and (n   i) ancestral alleles. When we don’t have
information about the ancestral allele, the folded SFS  = (h1, h2, . . . , hb n2 c) is
used, where hi records the fraction of segregating sites that have i minor alleles
and (n  i)major alleles. By definition, hi = xi+xn i1+d(i,n i) .
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A.1.4 Average pairwise difference per site (p)
Suppose we have n sequences sampled at present. We compare every two dif-
ferent sequences (thus there are (n2) pairs), count the number of differences be-
tween each pair, calculate the average of the total differences and normalize the
average difference by the total number of sites, or total length of loci L. This
quantity has the following relationship with the SFS and S:
p =
S
L(n2)
n 1
å
i=1
i(n  i)xi = SL(n2)
b n2 c
å
i=1
i(n  i)hi. (A.1)
A.1.5 Burden of private mutations (a)
Supposewe have n diploid individuals sequenced (thus there are 2n sequences).
a stands for the proportion of heterozygous positions in a newly sequenced
(n + 1)th individual that are novel. Namely, all of the previous n individuals
have the same genotype at such a site, but this newly sequenced individual
have a different genotype.
A.2 More detailed explanation of the growth speed parameter
bk
When rk , 0, the growth speed is controlled by the parameter bk. With the same
value of rk, Nk,f and (Tk   Tk 1), if bk > 1, the model will reach a Nk,i larger
than that of an exponential model. As a result, it is considered to be faster than
exponential or super-exponential. Similarly, if bk < 1, the model will reach a Nk,i
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smaller than that of an exponential model and thus is considered to be slower
than exponential or sub-exponential.
To illustrate the above facts, we give an example in Figure A.1(A). The
growth epoch starts 200 generations ago with a population size of 10,000. The
value of growth rate g = ddT logN(T) is fixed at 0.35% such that when exponen-
tial growth model is used, the population size after growth is 20,000, which is
a 2-fold growth. The values of b are chosen to be 0.9, 1 and 1.1. When b = 1.1,
the population size after growth is 67,730, larger than 20,000 when exponential
growth is considered. Similarly, when b = 0.9, the population size after growth
13,129, smaller than 20,000.
If we fix Nk,i, Nk,f and (Tk   Tk 1), as is mostly considered in this study,
taking different values of b will cause the growth pattern to be different. When
b > 1, the growth will show an accelerating pattern compared with exponential
growth; while when b < 1, the growth will show a decelerating pattern. To
illustrate this point, consider the models shown in Figure A.1(B). The growth
epoch is from 200 generations ago to present and the population sizes before
and after growth are fixed at 10,000 and 100,000 respectively. The values of b are
chosen to be 0.3, 1 and 1.7. For the exponential model, the growth rate 1.15% is
constant throughout the epoch. For b = 1.7, the growth rate (0.52%) is smaller
than that of the exponential growth (1.15%) at the onset time of 200 generations
ago. The growth keeps accelerating as time approaches present. At t = 0, the
growth rate for b = 1.7 (2.87%) is larger than that of the exponential (1.15%). For
b = 0.3, the pattern is opposite. The instantaneous growth rate (2.87%) is larger
than that of the exponential growth (115.13) at 200 generations ago. The growth
keeps decelerating as time approaches present. At t = 0, the instantaneous
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growth rate for b = 0.3 (0.57%) is smaller than that of the exponential (1.15%).
Figure A.1: Different patterns of generalized growth. (A) Illustration of the
population size functions when keeping the population size before growth Nf,
the growth time T and the parameter r the same and varying the growth speed
parameter b to be 0.5, 1.0 and 1.5. (B) Illustration of the population size func-
tions when keeping the population size before growth Nf, the population size
after growth Ni and the growth time T the same and varying the growth speed
parameter b to be 0.3, 1.0 and 1.7.
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A.3 Quantities Apj , V
p
j andW
p
i,j
For computing E[TpMRCA], the quantities A
p
j can be calculated by [111, 124, 125]
Apj =
( 1)j(2j  1)p[j]
p(j)
, (A.2)
where p[j] is the falling factorial function, p[j] = p(p  1)    (p  j+ 1), and p(j)
is the rising factorial function, p(j) = p(p+ 1)    (p+ j  1).
For computing E[p], the quantities Vpj can be calculated by [110]
Vpj = (2j  1)
p!(p  1)!
(p+ j  1)!(p  j)! [1+ ( 1)
j], (A.3)
andWpi,j are constants given by the following recursive relationships [110]:
Wpi,2 =
6
p+ 1
; (A.4)
Wpi,3 =
30(p  2i)
(p+ 1)(p+ 2)
; (A.5)
Wpi,j+2 =  
(1+ j)(3+ 2j)(p  j)
j(2j  1)(p+ j+ 1) W
p
i,j +
(3+ 2j)(p  2i)
j(p+ j+ 1)
Wpi,j+1. (A.6)
A.4 Expressions of rk
For the generalized growth models considered in this study, any epoch k is de-
termined by the starting population size Nk,i, the ending population size Nk,f,
the duration of the epoch (Tk   Tk 1) and the growth speed parameter bk. After
determining the epoch, the dependent parameter rk = rk(Nk,i,Nk,f, bk, Tk  Tk 1)
is calculated by
rk =
8><>:
N
1 bk
k,i  N
1 bk
k,f
Tk Tk 1 , bk , 1
logNk,i logNk,f
Tk Tk 1 , bk = 1
. (A.7)
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A.5 Expressions of L(T) for evaluating fkj
For convenient purposes, define lk(T) =
R T
Tk 1
ds/N (s), whereN (s) = 2N(s)
and Tk 1  T  Tk, then L(T) = L(Tk 1) + lk(T). For generalized models, the
solution for lk(T) is
lk(T) =
8>>>><>>>>:
T Tk 1
Nk,i , rk = 0
logNk,i logN (T)
rk
, bk = 0, rk , 0
N (T) bk N bkk,i
bkrk
, bk , 0, rk , 0
. (A.8)
Notice that the third expression above is also true for exponential
growth/decline (bk = 1 and rk , 0).
A.6 Evaluation of fkj for non-linear non-exponential general-
ized decline epochs
Generally, under arbitrary population size function N(T), the quantity
fkj = e
 ( j2)L(Tk 1)
Z Tk
Tk 1
e (
j
2)lk(T) dT, (A.9)
where L(T) =
R T
0 ds/N (s), lk(T) =
R T
Tk 1
ds/N (s) and N (s) = 2N(s).
For generalized decline epochs (rk < 0 and bk < f0, 1g), in which case we
didn’t find feasible closed-form expression for evaluating fkj , this quantity can
be expressed in the following way:
fkj =
e (
j
2)L(Tk 1)
( j2)
Z ( j2)
bkrk

N bkk,f  N
 bk
k,i

0
 
bkrk
( j2)
y+N bkk,i
!  1bk
e y dy. (A.10)
The integral
R ( j2)bkrk N bkk,f  N bkk,i 
0

bkrk
( j2)
y+N bkk,i
  1bk
e y dy is in the form ofR d
0 (ax + b)
ce x dx where a, b, c, d are constants. We numerically evaluate this
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integral by Gauss-Legendre quadrature [66]. The basic idea of Gauss-Legendre
quadrature is to approximate the integrated function f (x) = (ax+ b)ce x by a
polynomial function of degree n, and evaluate f (x) at n different points in the
range [0, d]. The error term is d
(2n+1)n!4
(2n+1)(2n)!3 f
2n(x) [66], where 0 < x < d and f (2n)
is the (2n)th derivative of f with respect to x. We choose the polynomial degree
n to be 512 in this work.
A.7 Libraries used/adapted in this study
For the computation of functions U (b, x) and M(b, x), we adapted
the C++ codes for the evaluation of confluent hypergeometric functions
from GSL scientific library. In addition, we used the library from
the link http://www.holoborodko.com/pavel/numerical-methods/numerical-
integration/, which is provided by Pavel Holoborodko for Gauss-Legendre
quadrature. The authors are grateful to the providers of these libraries, which
are essential in the implementation of the EGGS software.
A.8 Details of simulation parameters in the second section of
Results
When simulating the sequences, we used mutation rate m = 1.2 10 8 per base
pair per generation [75] and recombination rate r = 1.0 10 8 per base pair
per generation. To determine the amount of data for simulation, we used the
number of exomes given in [127], which is about 2,500 and assumed that each
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exome has 20,000 base pairs on average. To stress more the effect of linkage dis-
equilibrium (LD) between the alleles in each exome, we decreased the number
of independent loci to 1,000 and increased the length of each locus to 50,000,
while keeping the total number of base pairs the same. To reduce noise in the
simulated data and increase computation speed, we only kept the first 100 en-
tries of the folded SFS and calculated the aggregate sum of the rest entries, such
that there are 101 entries in total.
A.9 Details of bootstrapping
We used 200 bootstraps to obtain 95% confidence interval of the inferred param-
eters. For simulation studies, we randomly choose 1,000 loci from the simulated
1,000 independent loci with replacement in each bootstrap. For inference based
on ESP data [41, 127], we split the sequences into 500kb regions based on SNP
positions, which resulted in 882 different regions, similar to the number of loci
in simulation studies. In the same manner, we then chose 882 regions with re-
placement for each bootstrap.
A.10 Subsampling approach
For ESP data, the successful genotype counts vary across different segregating
sites. We applied the subsampling approach similarly considered in [42, 44]. For
a site with n successful genotype counts, suppose there are j minor alleles and
(n  j) major alleles, the probability that it is of xminor alleles when subsampled
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to m chromosomes is
P[x  m] = (
j
x)(
n j
m x)
(nm)
+
( jm x)(
n j
x )
(nm)
(A.11)
where x = 0, 1, 2,    , bm2 c. In this work, we choose m (the number of chro-
mosomes to subsample to) to be 7,740, which is 90% of the total number of
chromosomes (8,600).
A.11 Composite log likelihood
In order to determine the fitness of a model Q to the observed folded allele
frequency counts C, we compute the log likelihood of the model according to
L[Q] = logP[C jQ] =
b n2 c
å
i=1
Ci logE[hi jQ], (A.12)
where E[jQ] =

E [h1 jQ] ,E [h2 jQ] ,    ,E
h
hb n2 c jQ
i
is the expected
folded SFS given model Q. In this work, we considered SFS binning from
the 101st entry to reduce the noise in later parts of the SFS: E [e jQ] =
E [h1 jQ],E[h2 jQ] ,    ,E [h100 jQ] ,åb
n
2 c
i=1 E [hi jQ]

, and correspondingly the
binned allele frequency counts from the data eC = C1, C2,    , C100,åb n2 ci=1 Ci.
The log likelihood after binning is computed as
L[Q] = logP[eC jQ] = 101å
i=1
eCi logE[ehi jQ]. (A.13)
A.12 Goodness of fit measures
In order to test how well a model SFS fits the observed data, we performed c2
goodness of fit test. In specific, if the observed allele frequency counts is C =
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(C1, C2,    , Cd) (which indicates that the total number of observed segregating
sites is jCj) and the SFS under the model is  = (x1, x2,    , xd), then the statistic
c2 =
d
å
i=1
(Ci   jCjxi)2
jCjxi . (A.14)
The degree of freedom is (d  1), where d is the dimension of the vector C. A
p-value> 0.05 means we fail to reject the null hypothesis that the observed data
SFS is consistent with the model SFS.
We also used another measure, Kullback-Leibler divergence or KL diver-
gence [77], which provides a single number to relatively compare the goodness
of fit between different models:
DKL
 C
jCj
  = då
i=1
Ci
jCj

log
Ci
jCj   log xi

. (A.15)
A smallerDKLmeans a higher consistency between the observed and themodel.
The advantage of KL divergence over log likelihood is that KL divergence is a
normalized measure unaffected by the total number of observed segregating
sites jCj.
The p-values from c2 goodness of fit test and the KL divergence between the
observed ESP data and the SFS from each of the inferred models are shown in
Table S3.
A.13 Potential effect ofmulti-merger and simultaneous-merger
events on the SFS
As sample size increases, the probability of multi-merger and simultaneous-
merger events will rise, which violates the assumptions of Kingman’s coales-
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cent and might affect the SFS [6]. To test this effect, we used the discrete-
time Wright-Fisher (DTWF) model software [6] to compute the SFS under the
generalized Gazave et al. model with a sample size of 7,740. To shorten
the computation time, we used a hybrid of DTWF and Kingman’s coales-
cent with a time cutoff of tc = 212 generations. However, it is still com-
putationally burdensome to evaluate all 7,739 entries of the unnormalized SFS
XDTWF =
 
XDTWF1 ,X
DTWF
2 ,    ,XDTWF7739

, which is needed to compute the nor-
malized SFS DTWF = X
DTWF
jXDTWFj =
 
xDTWF1 , x
DTWF
2 ,    , xDTWF7739

as is used in the
inference work. We instead only evaluated the first 100 entries of XDTWF, 
XDTWF1 ,X
DTWF
2 ,    ,XDTWF100

.
We first compared the partially normalized SFS under DTWF model
DTWFpartial =
1
å100i=1 Xi
 
XDTWF1 ,X
DTWF
2 ,    ,XDTWF100

with the partially normalized SFS
under Kingman’s coalescent

Kingman
partial =
1
å100i=1 x
Kingman
i

x
Kingman
1 , x
Kingman
2 ,    , xKingman100

, which was computed
by EGGS. The two partially normalized SFS are very similar (Figure S9(A)). We
next compared the ratio of any entry to singletons under DTWF model and
Kingman’s coalescent,
rDTWFi =
XDTWFi
XDTWF1
; rKingmani =
x
Kingman
i
x
Kingman
1
, (A.16)
where i = 1, 2,    , 100 and we calculated the relative error,
e(i) =
rDTWFi   rKingmani
r
Kingman
i
 100%, (A.17)
where i = 1, 2,    , 100. The relative error is always less than 1% for the first
100 entries and asymptotically increases to 1% (Figure S9(B)). We then used 1%
as the relative error for the rest of the SFS entries to predict the full normalized
SFS under DTWF model. This predicted folded SFS is very similar to the folded
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SFS under Kingman’s coalescent (KL divergence = 6.14 10 6) and fits almost
equally well to the data (KL divergence between the predicted SFS and ESP data
= 1.24 10 4; p-value from c2 goodness of fit test = 1).
Figure A.2: The best-fit generalizedmodels for ESP data assuming the ancient
demography in Gazave et al. (2014) (red) and in Gravel et al. (2011) (blue).
The demographic historywas fixed before 620 generations ago for Gravel model
and 858 generations ago for Gravel model. Both x-axis and y-axis are on log
scale.
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Figure A.3: The one-dimensional log likelihood surface around the best es-
timates of the ESP synonymous data using exponential growth model. (A)
varying population size before growth while keeping all other parameters at
corresponding best estimates; (B) varying population size after growth only;
(C) varying growth time only.
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Figure A.4: The one-dimensional log likelihood surface around the best es-
timates of the ESP synonymous data using generalized growth model. (A)
varying population size before growth while keeping all other parameters at
corresponding best estimates; (B) varying population size after growth only;
(C) varying growth time only; (D) varying growth speed parameter only.
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Figure A.5: The first 20 entries of the site frequency spectra for ESP data
and the inferred demographic models assuming the ancient demography in
Gazave et al. (2014). The SFS from the ESP data, the exponential model, the
generalized growth model and the two-epoch exponential model are shown
in black, green, red and blue respectively. For comparison purposes, we also
included the SFS from a base model, which has a constant population size
throughout history (in pink).
97
BIBLIOGRAPHY
[1] ABDOU, A. G., MARAEE, A. H., AND REYAD, W. Immunohistochemical
expression of heat shock protein 70 in vitiligo. Ann Diagn Pathol 17, 3
(2013), 245–249.
[2] AHMETI, K. B., AJROUD-DRISS, S., AL-CHALABI, A., ANDERSEN, P. M.,
ARMSTRONG, J., BIRVE, A., BLAUW, H. M., BROWN, R. H., BRUIJN, L.,
CHEN, W., CHIO, A., COMEAU, M. C., CRONIN, S., DIEKSTRA, F. P., SO-
RAYA GKAZI, A., GLASS, J. D., GRAB, J. D., GROEN, E. J., HAINES, J. L.,
HARDIMAN, O., HELLER, S., HUANG, J., HUNG, W. Y., CONSORTIUM,
I., JAWORSKI, J. M., JONES, A., KHAN, H., LANDERS, J. E., LANGEFELD,
C. D., LEIGH, P. N., MARION, M. C., MCLAUGHLIN, R. L., MEININGER,
V., MELKI, J., MILLER, J. W., MORA, G., PERICAK-VANCE, M. A., RAM-
PERSAUD, E., ROBBERECHT, W., RUSSELL, L. P., SALACHAS, F., SARIS,
C. G., SHATUNOV, A., SHAW, C. E., SIDDIQUE, N., SIDDIQUE, T., SMITH,
B. N., SUFIT, R., TOPP, S., TRAYNOR, B. J., VANCE, C., VAN DAMME, P.,
VAN DEN BERG, L. H., VAN ES, M. A., VAN VUGHT, P. W., VELDINK,
J. H., YANG, Y., ZHENG, J. G., AND ALSGEN CONSORTIUM. Age of
onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1.
Neurobiol Aging 34, 1 (2013), 357.e7–357.e19.
[3] AHN, R., DING, Y. C., MURRAY, J., FASANO, A., GREEN, P. H.,
NEUHAUSEN, S. L., AND GARNER, C. Association analysis of the ex-
tended MHC region in celiac disease implicates multiple independent
susceptibility loci. PLoS One 7, 5 (2012), e36926.
[4] ARBIZA, L., GOTTIPATI, S., SIEPEL, A., AND KEINAN, A. Contrasting X-
linked and autosomal diversity across 14 human populations. Am J Hum
Genet 94, 6 (2014), 827–844.
[5] BARANZINI, S. E., WANG, J., GIBSON, R. A., GALWEY, N., NAEGELIN,
Y., BARKHOF, F., RADUE, E. W., LINDBERG, R. L., UITDEHAAG, B. M.,
JOHNSON, M. R., ANGELAKOPOULOU, A., HALL, L., RICHARDSON,
J. C., PRINJHA, R. K., GASS, A., GEURTS, J. J., KRAGT, J., SOMBEKKE,
M., VRENKEN, H., QUALLEY, P., LINCOLN, R. R., GOMEZ, R., CAIL-
LIER, S. J., GEORGE, M. F., MOUSAVI, H., GUERRERO, R., OKUDA, D. T.,
CREE, B. A., GREEN, A. J., WAUBANT, E., GOODIN, D. S., PELLETIER,
D., MATTHEWS, P. M., HAUSER, S. L., KAPPOS, L., POLMAN, C. H.,
AND OKSENBERG, J. R. Genome-wide association analysis of suscepti-
bility and clinical phenotype in multiple sclerosis. Hum Mol Genet 18, 4
(2009), 767–778.
98
[6] BHASKAR, A., CLARK, A. G., AND SONG, Y. S. Distortion of genealogical
properties when the sample is very large. Proc Natl Acad Sci U S A 111, 6
(2014), 2385–2390.
[7] BHASKAR, A., AND SONG, Y. S. Descartes’ Rule of Signs and the Identifi-
ability of Population Demographic Models from Genomic Variation Data.
Annals of Statistics 42, 6 (2014), 2469–2493.
[8] BHASKAR, A., WANG, Y. X., AND SONG, Y. S. Efficient inference of pop-
ulation size histories and locus-specific mutation rates from large-sample
genomic variation data. Genome Res 25, 2 (2015), 268–279.
[9] BIANCHI, I., LLEO, A., GERSHWIN, M. E., AND INVERNIZZI, P. The x
chromosome and immune associated genes. J Autoimmun 38, 2-3 (2012),
J187–J192.
[10] BIRLEA, S. A., JIN, Y., BENNETT, D. C., HERBSTMAN, D. M., WALLACE,
M. R., MCCORMACK, W. T., KEMP, E. H., GAWKRODGER, D. J., WEET-
MAN, A. P., PICARDO, M., LEONE, G., TAIEB, A., JOUARY, T., EZZEDINE,
K., VAN GEEL, N., LAMBERT, J., OVERBECK, A., FAIN, P. R., AND SPRITZ,
R. A. Comprehensive association analysis of candidate genes for gener-
alized vitiligo supports XBP1, FOXP3, and TSLP. J Invest Dermatol 131, 2
(2011), 371–381.
[11] BOWIE, L. J., REDDY, P. L., AND BECK, K. R. Alpha thalassemia and its
impact on other clinical conditions. Clin Lab Med 17, 1 (1997), 97–108.
[12] BRAUTBAR, A., BARBALIC, M., CHEN, F., BELMONT, J., VIRANI, S. S.,
SCHERER, S., HEGELE, R. A., AND BALLANTYNE, C. M. Rare APOA5
promoter variants associated with paradoxical HDL cholesterol decrease
in response to fenofibric acid therapy. J Lipid Res 54, 7 (2013), 1980–1987.
[13] BRAUTBAR, A., COVARRUBIAS, D., BELMONT, J., LARA-GARDUNO, F.,
VIRANI, S. S., JONES, P. H., LEAL, S. M., AND BALLANTYNE, C. M. Vari-
ants in the APOA5 gene region and the response to combination therapy
with statins and fenofibric acid in a randomized clinical trial of individu-
als with mixed dyslipidemia. Atherosclerosis 219, 2 (2011), 737–742.
[14] BRAUTBAR, A., VIRANI, S. S., BELMONT, J., NAMBI, V., JONES, P. H.,
AND BALLANTYNE, C. M. LPL gene variants affect apoC-III response to
combination therapy of statins and fenofibric acid in a randomized clini-
cal trial of individuals with mixed dyslipidemia. J Lipid Res 53, 3 (2012),
556–560.
99
[15] BROWN, M. B., AND FORSYTHE, A. B. Robust tests for equality of vari-
ances. Journal of the American Statistical Association 69, 346 (1974), 364–367.
[16] CARDONA, F., GUARDIOLA, M., QUEIPO-ORTUN˜O, M. I., MURRI, M.,
RIBALTA, J., AND TINAHONES, F. J. The -1131T>C SNP of the APOA5
gene modulates response to fenofibrate treatment in patients with the
metabolic syndrome: A postprandial study. Atherosclerosis 206, 1 (2009),
148–152.
[17] CARREL, L., AND WILLARD, H. F. X-inactivation profile reveals extensive
variability in X-linked gene expression in females. Nature 434, 7031 (2005),
400–404.
[18] CHANG, D., GAO, F., SLAVNEY, A., MA, L., WALDMAN, Y. Y., SAMS,
A. J., BILLING-ROSS, P., MADAR, A., SPRITZ, R., AND KEINAN, A. Ac-
counting for eXentricities: analysis of the X chromosome in GWAS reveals
X-linked genes implicated in autoimmune diseases. PLoS One 9, 12 (2014),
e113684.
[19] CHANG, D., AND KEINAN, A. Predicting signatures of “synthetic as-
sociations” and “natural associations” from empirical patterns of human
genetic variation. PLoS Comput Biol 8, 7 (2012), e1002600.
[20] CHARLESWORTH, B., MORGAN, M. T., AND CHARLESWORTH, D. The
effect of deleterious mutations on neutral molecular variation. Genetics
134, 4 (1993), 1289–1303.
[21] CHEN, H. The joint allele frequency spectrum of multiple populations:
a coalescent theory approach. Theoretical Population Biology 81, 2 (2012),
179–195.
[22] CHEN, H., HEY, J., AND CHEN, K. Inferring very recent population
growth rate from population-scale sequencing data: using a large-sample
coalescent estimator. Mol Biol Evol 32, 11 (2015), 2996–3011.
[23] CHIEN, K. L., LIN, Y. L., WEN, H. C., LIN H, P., YEN, C. T., LIN, S. W.,
AND KAO, J. T. Common sequence variant in lipoprotein lipase gene
conferring triglyceride response to fibrate treatment. Pharmacogenomics
10, 2 (2009), 267–276.
[24] CLAYTON, D. Testing for association on the X chromosome. Biostatistics
9, 4 (2008), 593–600.
100
[25] CLAYTON, D. G. Sex chromosomes and genetic association studies.
Genome Med 1, 11 (2009), 110.
[26] COHEN, J. C., BOERWINKLE, E., MOSLEY, T H, J., AND HOBBS, H. H.
Sequence variations in PCSK9, low LDL, and protection against coronary
heart disease. N Engl J Med 354, 12 (2006), 1264–1272.
[27] COHEN, J. C., KISS, R. S., PERTSEMLIDIS, A., MARCEL, Y. L., MCPHER-
SON, R., AND HOBBS, H. H. Multiple rare alleles contribute to low
plasma levels of HDL cholesterol. Science 305, 5685 (2004), 869–872.
[28] COTTON, A. M., LAM, L., AFFLECK, J. G., WILSON, I. M., PENAHER-
RERA, M. S., MCFADDEN, D. E., KOBOR, M. S., LAM, W. L., ROBINSON,
W. P., AND BROWN, C. J. Chromosome-wide DNA methylation analysis
predicts human tissue-specific X inactivation. Hum Genet 130, 2 (2011),
187–201.
[29] COVENTRY, A., BULL-OTTERSON, L. M., LIU, X., CLARK, A. G.,
MAXWELL, T. J., CROSBY, J., HIXSON, J. E., REA, T. J., MUZNY, D. M.,
LEWIS, L. R., WHEELER, D. A., SABO, A., LUSK, C., WEISS, K. G., AK-
BAR, H., CREE, A., HAWES, A. C., NEWSHAM, I., VARGHESE, R. T.,
VILLASANA, D., GROSS, S., JOSHI, V., SANTIBANEZ, J., MORGAN, M.,
CHANG, K., IV, W. H., TEMPLETON, A. R., BOERWINKLE, E., GIBBS, R.,
AND SING, C. F. Deep resequencing reveals excess rare recent variants
consistent with explosive population growth. Nat Commun 1 (2010), 131.
[30] CRONIN, S., BERGER, S., DING, J., SCHYMICK, J. C., WASHECKA, N.,
HERNANDEZ, D. G., GREENWAY, M. J., BRADLEY, D. G., TRAYNOR, B. J.,
AND HARDIMAN, O. A genome-wide association study of sporadic ALS
in a homogenous Irish population. Hum Mol Genet 17, 5 (2008), 768–774.
[31] DICKSON, S. P., WANG, K., KRANTZ, I., HAKONARSON, H., AND GOLD-
STEIN, D. B. Rare variants create synthetic genome-wide associations.
PLoS Biol 8, 1 (2010), e1000294.
[32] DISTECHE, C. M. Dosage compensation of the sex chromosomes. Annu
Rev Genet 46 (2012), 537–560.
[33] DUERR, R. H., TAYLOR, K. D., BRANT, S. R., RIOUX, J. D., SILVERBERG,
M. S., DALY, M. J., STEINHART, A. H., ABRAHAM, C., REGUEIRO, M.,
GRIFFITHS, A., DASSOPOULOS, T., BITTON, A., YANG, H., TARGAN, S.,
DATTA, L. W., KISTNER, E. O., SCHUMM, L. P., LEE, A. T., GREGERSEN,
101
P. K., BARMADA, M. M., ROTTER, J. I., NICOLAE, D. L., AND CHO, J. H.
A genome-wide association study identifies IL23R as an inflammatory
bowel disease gene. Science 314, 5804 (2006), 1461–1463.
[34] ELDON, B., BIRKNER, M., BLATH, J., AND FREUND, F. Can the site-
frequency spectrum distinguish exponential population growth from
multiple-merger coalescents? Genetics 199, 3 (2015), 841–856.
[35] EMERY, L. S., FELSENSTEIN, J., AND AKEY, J. M. Estimators of the human
effective sex ratio detect sex biases on different timescales. Am J Hum
Genet 87, 6 (2010), 848–856.
[36] EVANS, D. M., SPENCER, C. C., POINTON, J. J., SU, Z., HARVEY, D.,
KOCHAN, G., OPPERMANN, U., DILTHEY, A., PIRINEN, M., STONE,
M. A., APPLETON, L., MOUTSIANAS, L., LESLIE, S., WORDSWORTH,
T., KENNA, T. J., KARADERI, T., THOMAS, G. P., WARD, M. M., WEIS-
MAN, M. H., FARRAR, C., BRADBURY, L. A., DANOY, P., INMAN, R. D.,
MAKSYMOWYCH, W., GLADMAN, D., RAHMAN, P., SPONDYLOARTHRI-
TIS RESEARCH CONSORTIUM OF, C., MORGAN, A., MARZO-ORTEGA,
H., BOWNESS, P., GAFFNEY, K., GASTON, J. S., SMITH, M., BRUGES-
ARMAS, J., COUTO, A. R., SORRENTINO, R., PALADINI, F., FERREIRA,
M. A., XU, H., LIU, Y., JIANG, L., LOPEZ-LARREA, C., DIAZ-PENA,
R., LOPEZ-VAZQUEZ, A., ZAYATS, T., BAND, G., BELLENGUEZ, C.,
BLACKBURN, H., BLACKWELL, J. M., BRAMON, E., BUMPSTEAD, S. J.,
CASAS, J. P., CORVIN, A., CRADDOCK, N., DELOUKAS, P., DRONOV,
S., DUNCANSON, A., EDKINS, S., FREEMAN, C., GILLMAN, M., GRAY,
E., GWILLIAM, R., HAMMOND, N., HUNT, S. E., JANKOWSKI, J.,
JAYAKUMAR, A., LANGFORD, C., LIDDLE, J., MARKUS, H. S., MATHEW,
C. G., MCCANN, O. T., MCCARTHY, M. I., PALMER, C. N., PELTO-
NEN, L., PLOMIN, R., POTTER, S. C., RAUTANEN, A., RAVINDRARA-
JAH, R., RICKETTS, M., SAMANI, N., SAWCER, S. J., STRANGE, A.,
TREMBATH, R. C., VISWANATHAN, A. C., WALLER, M., WESTON, P.,
WHITTAKER, P., WIDAA, S., WOOD, N. W., MCVEAN, G., REVEILLE,
J. D., WORDSWORTH, B. P., BROWN, M. A., DONNELLY, P., AUSTRALO-
ANGLO-AMERICAN SPONDYLOARTHRITIS CONSORTIUM, AND WELL-
COME TRUST CASE CONTROL CONSORTIUM. Interaction between ERAP1
and HLA-B27 in ankylosing spondylitis implicates peptide handling in
the mechanism for HLA-B27 in disease susceptibility. Nat Genet 43, 8
(2011), 761–767.
[37] EXCOFFIER, L., DUPANLOUP, I., HUERTA-SANCHEZ, E., SOUSA, V. C.,
AND FOLL, M. Robust demographic inference from genomic and SNP
data. PLoS Genet 9, 10 (2013), e1003905.
102
[38] FAY, J. C., WYCKOFF, G. J., AND WU, C. I. Positive and negative selection
on the human genome. Genetics 158, 3 (2001), 1227–1234.
[39] FISHER, R. A. Statistical methods for research workers. Oliver and Boyd,
Edinburgh (UK), 1925.
[40] FRAZER, K. A., MURRAY, S. S., SCHORK, N. J., AND TOPOL, E. J. Human
genetic variation and its contribution to complex traits. Nat Rev Genet 10,
4 (2009), 241–251.
[41] FU, W., O’CONNOR, T. D., JUN, G., KANG, H. M., ABECASIS, G., LEAL,
S. M., GABRIEL, S., RIEDER, M. J., ALTSHULER, D., SHENDURE, J.,
NICKERSON, D. A., BAMSHAD, M. J., PROJECT, N. E. S., AND AKEY,
J. M. Analysis of 6,515 exomes reveals the recent origin of most human
protein-coding variants. Nature 493, 7431 (2013), 216–220.
[42] GAO, F., AND KEINAN, A. High burden of private mutations due to ex-
plosive human population growth and purifying selection. BMCGenomics
15 Suppl 4 (2014), S3.
[43] GAO, F., AND KEINAN, A. Explosive genetic evidence for explosive hu-
man population growth. Curr Opin Genet Dev 41 (2016), 130–139.
[44] GAZAVE, E., MA, L., CHANG, D., COVENTRY, A., GAO, F., MUZNY, D.,
BOERWINKLE, E., GIBBS, R. A., SING, C. F., CLARK, A. G., AND KEINAN,
A. Neutral genomic regions refine models of recent rapid human popu-
lation growth. Proc Natl Acad Sci U S A 111, 2 (2014), 757–762.
[45] GIBSON, G. Rare and common variants: twenty arguments. Nat Rev Genet
13, 2 (2012), 135–145.
[46] GILKS, W. P., ABBOTT, J. K., AND MORROW, E. H. Sex differences in
disease genetics: evidence, evolution, and detection. Trends Genet 30, 10
(2014), 453–463.
[47] GOTTIPATI, S., ARBIZA, L., SIEPEL, A., CLARK, A. G., AND KEINAN, A.
Analyses of X-linked and autosomal genetic variation in population-scale
whole genome sequencing. Nat Genet 43, 8 (2011), 741–743.
[48] GRADSHTEI˘N, I. S., RYZHIK, I. M., AND JEFFREY, A. Table of integrals,
series, and products, 7th ed. Academic Press, Amsterdam; Boston, 2007.
103
[49] GRAVEL, S., HENN, B. M., GUTENKUNST, R. N., INDAP, A. R., MARTH,
G. T., CLARK, A. G., YU, F., GIBBS, R. A., GENOMES, P., AND BUSTA-
MANTE, C. D. Demographic history and rare allele sharing among human
populations. Proc Natl Acad Sci U S A 108, 29 (2011), 11983–11988.
[50] GUTENKUNST, R. N., HERNANDEZ, R. D., WILLIAMSON, S. H., AND
BUSTAMANTE, C. D. Inferring the joint demographic history of multiple
populations frommultidimensional SNP frequency data. PLoS Genet 5, 10
(2009), e1000695.
[51] HAMMER, M. F., MENDEZ, F. L., COX, M. P., WOERNER, A. E., AND
WALL, J. D. Sex-biased evolutionary forces shape genomic patterns of
human diversity. PLoS Genet 4, 9 (2008), e1000202.
[52] HAMMER, M. F., WOERNER, A. E., MENDEZ, F. L., WATKINS, J. C., COX,
M. P., AND WALL, J. D. The ratio of human x chromosome to autosome
diversity is positively correlated with genetic distance from genes. Nat
Genet 42, 10 (2010), 830–831.
[53] HARRIS, K., AND NIELSEN, R. Inferring demographic history from a
spectrum of shared haplotype lengths. PLoS Genet 9, 6 (2013), e1003521.
[54] HOWIE, B., FUCHSBERGER, C., STEPHENS, M., MARCHINI, J., AND
ABECASIS, G. R. Fast and accurate genotype imputation in genome-wide
association studies through pre-phasing. Nat Genet 44, 8 (2012), 955–959.
[55] HUDSON, R. R. Generating samples under aWright-Fisher neutral model
of genetic variation. Bioinformatics 18, 2 (2002), 337–338.
[56] HUYNH, K. D., FISCHLE, W., VERDIN, E., AND BARDWELL, V. J. BCoR,
a novel corepressor involved in BCL-6 repression. Genes Dev 14, 14 (2000),
1810–1823.
[57] INTERNATIONAL MULTIPLE SCLEROSIS GENETICS CONSORTIUM, WELL-
COME TRUST CASE CONTROL CONSORTIUM, SAWCER, S., HELLENTHAL,
G., PIRINEN, M., SPENCER, C. C., PATSOPOULOS, N. A., MOUTSIANAS,
L., DILTHEY, A., SU, Z., FREEMAN, C., HUNT, S. E., EDKINS, S., GRAY,
E., BOOTH, D. R., POTTER, S. C., GORIS, A., BAND, G., OTURAI, A. B.,
STRANGE, A., SAARELA, J., BELLENGUEZ, C., FONTAINE, B., GILLMAN,
M., HEMMER, B., GWILLIAM, R., ZIPP, F., JAYAKUMAR, A., MARTIN, R.,
LESLIE, S., HAWKINS, S., GIANNOULATOU, E., D’ALFONSO, S., BLACK-
BURN, H., MARTINELLI BONESCHI, F., LIDDLE, J., HARBO, H. F., PEREZ,
104
M. L., SPURKLAND, A., WALLER, M. J., MYCKO, M. P., RICKETTS,
M., COMABELLA, M., HAMMOND, N., KOCKUM, I., MCCANN, O. T.,
BAN, M., WHITTAKER, P., KEMPPINEN, A., WESTON, P., HAWKINS, C.,
WIDAA, S., ZAJICEK, J., DRONOV, S., ROBERTSON, N., BUMPSTEAD,
S. J., BARCELLOS, L. F., RAVINDRARAJAH, R., ABRAHAM, R., ALFREDS-
SON, L., ARDLIE, K., AUBIN, C., BAKER, A., BAKER, K., BARANZINI,
S. E., BERGAMASCHI, L., BERGAMASCHI, R., BERNSTEIN, A., BERTHELE,
A., BOGGILD, M., BRADFIELD, J. P., BRASSAT, D., BROADLEY, S. A.,
BUCK, D., BUTZKUEVEN, H., CAPRA, R., CARROLL, W. M., CAVALLA,
P., CELIUS, E. G., CEPOK, S., CHIAVACCI, R., CLERGET-DARPOUX, F.,
CLYSTERS, K., COMI, G., COSSBURN, M., COURNU-REBEIX, I., COX,
M. B., COZEN, W., CREE, B. A., CROSS, A. H., CUSI, D., DALY, M. J.,
DAVIS, E., DE BAKKER, P. I., DEBOUVERIE, M., D’HOOGHE M, B.,
DIXON, K., DOBOSI, R., DUBOIS, B., ELLINGHAUS, D., ELOVAARA, I.,
ESPOSITO, F., FONTENILLE, C., FOOTE, S., FRANKE, A., GALIMBERTI,
D., GHEZZI, A., GLESSNER, J., GOMEZ, R., GOUT, O., GRAHAM, C.,
GRANT, S. F., GUERINI, F. R., HAKONARSON, H., HALL, P., HAMSTEN,
A., HARTUNG, H. P., HEARD, R. N., HEATH, S., HOBART, J., HOSHI, M.,
INFANTE-DUARTE, C., INGRAM, G., INGRAM, W., ISLAM, T., JAGODIC,
M., KABESCH, M., KERMODE, A. G., KILPATRICK, T. J., KIM, C., KLOPP,
N., KOIVISTO, K., LARSSON, M., LATHROP, M., LECHNER-SCOTT, J. S.,
LEONE, M. A., LEPPA, V., LILJEDAHL, U., BOMFIM, I. L., LINCOLN,
R. R., LINK, J., LIU, J., LORENTZEN, A. R., LUPOLI, S., MACCIARDI, F.,
MACK, T., MARRIOTT, M., MARTINELLI, V., MASON, D., MCCAULEY,
J. L., MENTCH, F., MERO, I. L., MIHALOVA, T., MONTALBAN, X., MOT-
TERSHEAD, J., MYHR, K. M., NALDI, P., OLLIER, W., PAGE, A., PALOTIE,
A., PELLETIER, J., PICCIO, L., PICKERSGILL, T., PIEHL, F., POBYWA-
JLO, S., QUACH, H. L., RAMSAY, P. P., REUNANEN, M., REYNOLDS,
R., RIOUX, J. D., RODEGHER, M., ROESNER, S., RUBIO, J. P., RUCK-
ERT, I. M., SALVETTI, M., SALVI, E., SANTANIELLO, A., SCHAEFER,
C. A., SCHREIBER, S., SCHULZE, C., SCOTT, R. J., SELLEBJERG, F., SEL-
MAJ, K. W., SEXTON, D., SHEN, L., SIMMS-ACUNA, B., SKIDMORE, S.,
SLEIMAN, P. M., SMESTAD, C., SORENSEN, P. S., SONDERGAARD, H. B.,
STANKOVICH, J., STRANGE, R. C., SULONEN, A. M., SUNDQVIST, E.,
SYVANEN, A. C., TADDEO, F., TAYLOR, B., BLACKWELL, J. M., TIEN-
ARI, P., BRAMON, E., TOURBAH, A., BROWN, M. A., TRONCZYNSKA,
E., CASAS, J. P., TUBRIDY, N., CORVIN, A., VICKERY, J., JANKOWSKI,
J., VILLOSLADA, P., MARKUS, H. S., WANG, K., MATHEW, C. G., WA-
SON, J., PALMER, C. N., WICHMANN, H. E., PLOMIN, R., WILLOUGHBY,
E., RAUTANEN, A., WINKELMANN, J., WITTIG, M., TREMBATH, R. C.,
YAOUANQ, J., VISWANATHAN, A. C., ZHANG, H., WOOD, N. W.,
ZUVICH, R., DELOUKAS, P., LANGFORD, C., DUNCANSON, A., OK-
SENBERG, J. R., PERICAK-VANCE, M. A., HAINES, J. L., OLSSON, T.,
HILLERT, J., IVINSON, A. J., DE JAGER, P. L., PELTONEN, L., STEWART,
105
G. J., HAFLER, D. A., HAUSER, S. L., MCVEAN, G., DONNELLY, P., AND
COMPSTON, A. Genetic risk and a primary role for cell-mediated immune
mechanisms in multiple sclerosis. Nature 476, 7359 (2011), 214–219.
[58] JIANG, B., ZHANG, X., ZUO, Y., AND KANG, G. A powerful truncated
tail strength method for testing multiple null hypotheses in one dataset. J
Theor Biol 277, 1 (2011), 67–73.
[59] JIN, X., CHEN, Y. P., CHEN, S. H., AND XIANG, Z. Association between
Helicobacter Pylori infection and ulcerative colitis–a case control study
from China. Int J Med Sci 10, 11 (2013), 1479–1484.
[60] JIN, Y., BIRLEA, S. A., FAIN, P. R., FERRARA, T. M., BEN, S., RIC-
CARDI, S. L., COLE, J. B., GOWAN, K., HOLLAND, P. J., BENNETT, D. C.,
LUITEN, R. M., WOLKERSTORFER, A., VAN DER VEEN, J. P., HART-
MANN, A., EICHNER, S., SCHULER, G., VAN GEEL, N., LAMBERT, J.,
KEMP, E. H., GAWKRODGER, D. J., WEETMAN, A. P., TAIEB, A., JOUARY,
T., EZZEDINE, K., WALLACE, M. R., MCCORMACK, W. T., PICARDO,
M., LEONE, G., OVERBECK, A., SILVERBERG, N. B., AND SPRITZ, R. A.
Genome-wide association analyses identify 13 new susceptibility loci for
generalized vitiligo. Nat Genet 44, 6 (2012), 676–680.
[61] JIN, Y., BIRLEA, S. A., FAIN, P. R., GOWAN, K., RICCARDI, S. L., HOL-
LAND, P. J., MAILLOUX, C. M., SUFIT, A. J., HUTTON, S. M., AMADI-
MYERS, A., BENNETT, D. C., WALLACE, M. R., MCCORMACK, W. T.,
KEMP, E. H., GAWKRODGER, D. J., WEETMAN, A. P., PICARDO, M.,
LEONE, G., TAIEB, A., JOUARY, T., EZZEDINE, K., VAN GEEL, N., LAM-
BERT, J., OVERBECK, A., AND SPRITZ, R. A. Variant of TYR and autoim-
munity susceptibility loci in generalized vitiligo. N Engl J Med 362, 18
(2010), 1686–1697.
[62] JOHANSEN, C. T., AND HEGELE, R. A. Genetic bases of hypertriglyceri-
demic phenotypes. Curr Opin Lipidol 22, 4 (2011), 247–253.
[63] JONES, P. H., BAYS, H. E., DAVIDSON, M. H., KELLY, M. T., BUTTLER,
S. M., SETZE, C. M., SLEEP, D. J., AND STOLZENBACH, J. C. Evaluation
of a new formulation of fenofibric acid, ABT-335, co-administered with
statins: study design and rationale of a phase III clinical programme. Clin
Drug Investig 28, 10 (2008), 625–634.
[64] JONES, P. H., DAVIDSON, M. H., KASHYAP, M. L., KELLY, M. T., BUT-
TLER, S. M., SETZE, C. M., SLEEP, D. J., AND STOLZENBACH, J. C. Effi-
cacy and safety of ABT-335 (fenofibric acid) in combination with rosuvas-
106
tatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis
204, 1 (2009), 208–215.
[65] JU, T., AND CUMMINGS, R. D. Protein glycosylation: chaperonemutation
in Tn syndrome. Nature 437, 7063 (2005), 1252.
[66] KAHANER, D., MOLER, C. B., NASH, S., AND FORSYTHE, G. E. Numerical
methods and software. Prentice Hall, Englewood Cliffs, N.J., 1988.
[67] KEINAN, A., AND CLARK, A. G. Recent explosive human population
growth has resulted in an excess of rare genetic variants. Science 336, 6082
(2012), 740–743.
[68] KEINAN, A., MULLIKIN, J. C., PATTERSON, N., AND REICH, D. Mea-
surement of the human allele frequency spectrum demonstrates greater
genetic drift in East Asians than in Europeans. Nat Genet 39, 10 (2007),
1251–1255.
[69] KEINAN, A., MULLIKIN, J. C., PATTERSON, N., AND REICH, D. Accel-
erated genetic drift on chromosome X during the human dispersal out of
Africa. Nat Genet 41, 1 (2009), 66–70.
[70] KEINAN, A., AND REICH, D. Can a sex-biased human demography ac-
count for the reduced effective population size of chromosome x in non-
africans? Mol Biol Evol 27, 10 (2010), 2312–2321.
[71] KIEZUN, A., GARIMELLA, K., DO, R., STITZIEL, N. O., NEALE, B. M.,
MCLAREN, P. J., GUPTA, N., SKLAR, P., SULLIVAN, P. F., MORAN, J. L.,
HULTMAN, C. M., LICHTENSTEIN, P., MAGNUSSON, P., LEHNER, T.,
SHUGART, Y. Y., PRICE, A. L., DE BAKKER, P. I., PURCELL, S. M., AND
SUNYAEV, S. Exome sequencing and the genetic basis of complex traits.
Nat Genet 44, 6 (2012), 623–630.
[72] KIMURA, M., AND OHTA, T. The age of a neutral mutant persisting in a
finite population. Genetics 75, 1 (1973), 199–212.
[73] KINGMAN, K. F. C. On the genealogy of large populations. J Appl Probab
19 (1982), 27–43.
[74] KINGMAN, K. F. C. The coalescent. Stochastic Process Appl 13, 3 (1982),
235–248.
107
[75] KONG, A., FRIGGE, M. L., MASSON, G., BESENBACHER, S., SULEM, P.,
MAGNUSSON, G., GUDJONSSON, S. A., SIGURDSSON, A., JONASDOT-
TIR, A., JONASDOTTIR, A., WONG, W. S., SIGURDSSON, G., WALTERS,
G. B., STEINBERG, S., HELGASON, H., THORLEIFSSON, G., GUDBJARTS-
SON, D. F., HELGASON, A., MAGNUSSON, O. T., THORSTEINSDOTTIR,
U., AND STEFANSSON, K. Rate of de novo mutations and the importance
of father’s age to disease risk. Nature 488, 7412 (2012), 471–475.
[76] KORN, J. M., KURUVILLA, F. G., MCCARROLL, S. A., WYSOKER, A.,
NEMESH, J., CAWLEY, S., HUBBELL, E., VEITCH, J., COLLINS, P. J.,
DARVISHI, K., LEE, C., NIZZARI, M. M., GABRIEL, S. B., PURCELL, S.,
DALY, M. J., AND ALTSHULER, D. Integrated genotype calling and asso-
ciation analysis of SNPs, common copy number polymorphisms and rare
CNVs. Nat Genet 40, 10 (2008), 1253–1260.
[77] KULLBACK, S., AND LEIBLER, R. A. On information and sufficiency. Ann
Math Stat 22, 1 (1951), 79–86.
[78] LAAKSOVIRTA, H., PEURALINNA, T., SCHYMICK, J. C., SCHOLZ, S. W.,
LAI, S. L., MYLLYKANGAS, L., SULKAVA, R., JANSSON, L., HERNANDEZ,
D. G., GIBBS, J. R., NALLS, M. A., HECKERMAN, D., TIENARI, P. J., AND
TRAYNOR, B. J. Chromosome 9p21 in amyotrophic lateral sclerosis in
Finland: a genome-wide association study. Lancet Neurol 9, 10 (2010),
978–985.
[79] LAI, C. Q., ARNETT, D. K., CORELLA, D., STRAKA, R. J., TSAI,
M. Y., PEACOCK, J. M., ADICONIS, X., PARNELL, L. D., HIXSON, J. E.,
PROVINCE, M. A., AND ORDOVAS, J. M. Fenofibrate effect on triglyceride
and postprandial response of Apolipoprotein A5 variants: the GOLDN
study. Arterioscler Thromb Vasc Biol 27, 6 (2007), 1417–1425.
[80] LAMBERT, C. A., CONNELLY, C. F., MADEOY, J., QIU, R., OLSON, M.,
AND AKEY, J. M. Highly punctuated patterns of population structure on
the X chromosome and implications for African evolutionary history. Am
J Hum Genet 86, 1 (2010), 34–44.
[81] LERNER, D. J., AND KANNEL, W. B. Patterns of coronary heart disease
morbidity and mortality in the sexes: a 26-year follow-up of the Framing-
ham population. Am Heart J 111, 2 (1986), 383–390.
[82] LI, B., AND LEAL, S. M. Methods for detecting associations with rare
variants for common diseases: application to analysis of sequence data.
Am J Hum Genet 83, 3 (2008), 311–321.
108
[83] LI, H., AND DURBIN, R. Inference of human population history from
individual whole-genome sequences. Nature 475, 7357 (2011), 493–496.
[84] LI, Y. R., LI, J., ZHAO, S. D., BRADFIELD, J. P., MENTCH, F. D., MAG-
GADOTTIR, S. M., HOU, C., ABRAMS, D. J., CHANG, D., GAO, F., GUO,
Y., WEI, Z., CONNOLLY, J. J., CARDINALE, C. J., BAKAY, M., GLESSNER,
J. T., LI, D., KAO, C., THOMAS, K. A., QIU, H., CHIAVACCI, R. M.,
KIM, C. E., WANG, F., SNYDER, J., RICHIE, M. D., FLATO, B., FORRE,
O., DENSON, L. A., THOMPSON, S. D., BECKER, M. L., GUTHERY, S. L.,
LATIANO, A., PEREZ, E., RESNICK, E., RUSSELL, R. K., WILSON, D. C.,
SILVERBERG, M. S., ANNESE, V., LIE, B. A., PUNARO, M., DUBINSKY,
M. C., MONOS, D. S., STRISCIUGLIO, C., STAIANO, A., MIELE, E., KU-
GATHASAN, S., ELLIS, J. A., MUNRO, J. E., SULLIVAN, K. E., WISE,
C. A., CHAPEL, H., CUNNINGHAM-RUNDLES, C., GRANT, S. F., OR-
ANGE, J. S., SLEIMAN, P. M., BEHRENS, E. M., GRIFFITHS, A. M., SAT-
SANGI, J., FINKEL, T. H., KEINAN, A., PRAK, E. T., POLYCHRONAKOS,
C., BALDASSANO, R. N., LI, H., KEATING, B. J., AND HAKONARSON, H.
Meta-analysis of shared genetic architecture across ten pediatric autoim-
mune diseases. Nat Med 21, 9 (2015), 1018–1027.
[85] LIBERT, C., DEJAGER, L., AND PINHEIRO, I. The X chromosome in im-
mune functions: when a chromosome makes the difference. Nat Rev Im-
munol 10, 8 (2010), 594–604.
[86] LIU, J. Z., MCRAE, A. F., NYHOLT, D. R., MEDLAND, S. E., WRAY, N. R.,
BROWN, K. M., INVESTIGATORS, A., HAYWARD, N. K., MONTGOMERY,
G. W., VISSCHER, P. M., MARTIN, N. G., AND MACGREGOR, S. A versa-
tile gene-based test for genome-wide association studies. Am J Hum Genet
87, 1 (2010), 139–145.
[87] LIU, X., AND FU, Y. X. Exploring population size changes using SNP
frequency spectra. Nat Genet 47, 5 (2015), 555–559.
[88] LIU, Y., ORDOVAS, J. M., GAO, G., PROVINCE, M., STRAKA, R. J.,
TSAI, M. Y., LAI, C. Q., ZHANG, K., BORECKI, I., HIXSON, J. E., AL-
LISON, D. B., AND ARNETT, D. K. Pharmacogenetic association of the
APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the
genetics of lipid-lowering drugs and diet network study. Pharmacogenet
Genomics 19, 2 (2009), 161–169.
[89] LOHMUELLER, K. E., DEGENHARDT, J. D., AND KEINAN, A. Sex-
averaged recombination andmutation rates on the X chromosome: a com-
109
ment on Labuda et al. Am J Hum Genet 86, 6 (2010), 978–980; author reply
980–981.
[90] LOLEY, C., ZIEGLER, A., AND KONIG, I. R. Association tests for X-
chromosomalmarkers–a comparison of different test statistics. HumHered
71, 1 (2011), 23–36.
[91] LUTHER, J., DAVE, M., HIGGINS, P. D., AND KAO, J. Y. Association
between Helicobacter pylori infection and inflammatory bowel disease: a
meta-analysis and systematic review of the literature. Inflamm Bowel Dis
16, 6 (2010), 1077–1084.
[92] MA, L., BALLANTYNE, C. M., BELMONT, J. W., KEINAN, A., AND
BRAUTBAR, A. Interaction between SNPs in the RXRA and near
ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid
therapy in individuals with mixed dyslipidemia. J Lipid Res 53, 11 (2012),
2425–2428.
[93] MA, L., CLARK, A. G., AND KEINAN, A. Gene-based testing of interac-
tions in association studies of quantitative traits. PLoS Genet 9, 2 (2013),
e1003321.
[94] MA, L., HOFFMAN, G., AND KEINAN, A. X-inactivation informs
variance-based testing for X-linked association of a quantitative trait.
BMC Genomics 16 (2015), 241.
[95] MACLEOD, I. M., LARKIN, D. M., LEWIN, H. A., HAYES, B. J., AND
GODDARD, M. E. Inferring demography from runs of homozygosity in
whole-genome sequence, with correction for sequence errors. Mol Biol
Evol 30, 9 (2013), 2209–2223.
[96] MAHER, B. Personal genomes: The case of the missing heritability. Nature
456, 7218 (2008), 18–21.
[97] MAILMAN, M. D., FEOLO, M., JIN, Y., KIMURA, M., TRYKA, K.,
BAGOUTDINOV, R., HAO, L., KIANG, A., PASCHALL, J., PHAN, L.,
POPOVA, N., PRETEL, S., ZIYABARI, L., LEE, M., SHAO, Y., WANG, Z. Y.,
SIROTKIN, K., WARD, M., KHOLODOV, M., ZBICZ, K., BECK, J., KIMEL-
MAN, M., SHEVELEV, S., PREUSS, D., YASCHENKO, E., GRAEFF, A., OS-
TELL, J., AND SHERRY, S. T. The NCBI dbGaP database of genotypes and
phenotypes. Nat Genet 39, 10 (2007), 1181–1186.
110
[98] MANOLIO, T. A., COLLINS, F. S., COX, N. J., GOLDSTEIN, D. B., A,
H. L., HUNTER, D. J., MCCARTHY, M. I., RAMOS, E. M., CARDON,
L. R., CHAKRAVARTI, A., CHO, J. H., GUTTMACHER, A. E., KONG, A.,
KRUGLYAK, L., MARDIS, E., ROTIMI, C. N., SLATKIN, M., VALLE, D.,
S, W. A., BOEHNKE, M., CLARK, A. G., EICHLER, E. E., GIBSON, G.,
HAINES, J. L., MACKAY, T. F., MCCARROLL, S. A., AND VISSCHER, P. M.
Finding the missing heritability of complex diseases. Nature 461, 7265
(2009), 747–753.
[99] MARTH, G. T., CZABARKA, E., MURVAI, J., AND SHERRY, S. T. The allele
frequency spectrum in genome-wide human variation data reveals sig-
nals of differential demographic history in three large world populations.
Genetics 166, 1 (2004), 351–372.
[100] MATANOSKI, G., TAO, X., ALMON, L., ADADE, A. A., AND DAVIES-
COLE, J. O. Demographics and tumor characteristics of colorectal cancers
in the united states, 1998-2001. Cancer 107, 5 Suppl (2006), 1112–1120.
[101] MENG, X. L., AND RUBIN, D. B. Maximum-likelihood-estimation via the
ECM algorithm – a general framework. Biometrika 80, 2 (1993), 267–278.
[102] MORGENTHALER, S., AND THILLY, W. G. A strategy to discover genes
that carry multi-allelic or mono-allelic risk for common diseases: a cohort
allelic sums test (CAST). Mutat Res 615, 1-2 (2007), 28–56.
[103] MORRIS, A. P., AND ZEGGINI, E. An evaluation of statistical approaches
to rare variant analysis in genetic association studies. Genet Epidemiol 34,
2 (2010), 188–193.
[104] MOSENSON, J. A., EBY, J. M., HERNANDEZ, C., AND LE POOLE, I. C.
A central role for inducible heat-shock protein 70 in autoimmune vitiligo.
Exp Dermatol 22, 9 (2013), 566–9.
[105] MOSENSON, J. A., ZLOZA, A., KLARQUIST, J., BARFUSS, A. J.,
GUEVARA-PATINO, J. A., AND POOLE, I. C. HSP70i is a critical com-
ponent of the immune response leading to vitiligo. Pigment Cell Melanoma
Res 25, 1 (2012), 88–98.
[106] MUSCAT, J. E., RICHIE, J P, J., THOMPSON, S., AND WYNDER, E. L. Gen-
der differences in smoking and risk for oral cancer. Cancer Res 56, 22
(1996), 5192–5197.
111
[107] NAIR, R. P., DUFFIN, K. C., HELMS, C., DING, J., STUART, P. E.,
GOLDGAR, D., GUDJONSSON, J. E., LI, Y., TEJASVI, T., FENG, B. J.,
RUETHER, A., SCHREIBER, S., WEICHENTHAL, M., GLADMAN, D., RAH-
MAN, P., SCHRODI, S. J., PRAHALAD, S., GUTHERY, S. L., FISCHER, J.,
LIAO, W., KWOK, P. Y., MENTER, A., LATHROP, G. M., WISE, C. A., BE-
GOVICH, A. B., VOORHEES, J. J., ELDER, J. T., KRUEGER, G. G., BOW-
COCK, A. M., ABECASIS, G. R., AND COLLABORATIVE ASSOCIATION
STUDY OF PSORIASIS. Genome-wide scan reveals association of psoria-
sis with IL-23 and NF-kappaB pathways. Nat Genet 41, 2 (2009), 199–204.
[108] NELSON, M. R., WEGMANN, D., EHM, M. G., KESSNER, D., ST JEAN, P.,
VERZILLI, C., SHEN, J., TANG, Z., BACANU, S. A., FRASER, D., WAR-
REN, L., APONTE, J., ZAWISTOWSKI, M., LIU, X., ZHANG, H., ZHANG,
Y., LI, J., LI, Y., LI, L., WOOLLARD, P., TOPP, S., HALL, M. D., NANGLE,
K., WANG, J., ABECASIS, G., CARDON, L. R., ZOLLNER, S., WHITTAKER,
J. C., CHISSOE, S. L., NOVEMBRE, J., AND MOOSER, V. An abundance
of rare functional variants in 202 drug target genes sequenced in 14,002
people. Science 337, 6090 (2012), 100–104.
[109] OBER, C., LOISEL, D. A., AND GILAD, Y. Sex-specific genetic architecture
of human disease. Nat Rev Genet 9, 12 (2008), 911–922.
[110] POLANSKI, A., BOBROWSKI, A., AND KIMMEL, M. A note on distribu-
tions of times to coalescence, under time-dependent population size. The-
oretical Population Biology 63, 1 (2003), 33–40.
[111] POLANSKI, A., AND KIMMEL, M. New explicit expressions for relative
frequencies of single-nucleotide polymorphisms with application to sta-
tistical inference on population growth. Genetics 165, 1 (2003), 427–436.
[112] PRICE, A. L., PATTERSON, N. J., PLENGE, R. M., WEINBLATT, M. E.,
SHADICK, N. A., AND REICH, D. Principal components analysis cor-
rects for stratification in genome-wide association studies. Nat Genet 38, 8
(2006), 904–909.
[113] PURCELL, S., NEALE, B., TODD-BROWN, K., THOMAS, L., FERREIRA,
M. A., BENDER, D., MALLER, J., SKLAR, P., DE BAKKER, P. I., DALY,
M. J., AND SHAM, P. C. PLINK: a tool set for whole-genome association
and population-based linkage analyses. Am J Hum Genet 81, 3 (2007), 559–
575.
[114] QI, L., CORNELIS, M. C., KRAFT, P., STANYA, K. J., LINDA KAO, W. H.,
PANKOW, J. S., DUPUIS, J., FLOREZ, J. C., FOX, C. S., PARE, G., SUN, Q.,
112
GIRMAN, C. J., LAURIE, C. C., MIREL, D. B., MANOLIO, T. A., CHAS-
MAN, D. I., BOERWINKLE, E., RIDKER, P. M., HUNTER, D. J., MEIGS,
J. B., LEE, C. H., HU, F. B., VAN DAM, R. M., META-ANALYSIS OF
GLUCOSE AND INSULIN-RELATED TRAITS CONSORTIUM (MAGIC), AND
DIABETES GENETICS REPLICATION AND META-ANALYSIS (DIAGRAM)
CONSORTIUM. Genetic variants at 2q24 are associated with susceptibility
to type 2 diabetes. Hum Mol Genet 19, 13 (2010), 2706–15.
[115] QUINTERO, O. L., AMADOR-PATARROYO, M. J., MONTOYA-ORTIZ, G.,
ROJAS-VILLARRAGA, A., AND ANAYA, J. M. Autoimmune disease and
gender: plausible mechanisms for the female predominance of autoim-
munity. J Autoimmun 38, 2–3 (2012), J109–J119.
[116] RANDALL, J. C., WINKLER, T. W., KUTALIK, Z., BERNDT, S. I., JACK-
SON, A. U., MONDA, K. L., KILPELAINEN, T. O., ESKO, T., MAGI,
R., LI, S., WORKALEMAHU, T., FEITOSA, M. F., CROTEAU-CHONKA,
D. C., DAY, F. R., FALL, T., FERREIRA, T., GUSTAFSSON, S., LOCKE,
A. E., MATHIESON, I., SCHERAG, A., VEDANTAM, S., WOOD, A. R.,
LIANG, L., STEINTHORSDOTTIR, V., THORLEIFSSON, G., DERMITZAKIS,
E. T., DIMAS, A. S., KARPE, F., MIN, J. L., NICHOLSON, G., CLEGG,
D. J., PERSON, T., KROHN, J. P., BAUER, S., BUECHLER, C., EISINGER,
K., CONSORTIUM, D., BONNEFOND, A., FROGUEL, P., INVESTIGATORS,
M., HOTTENGA, J. J., PROKOPENKO, I., WAITE, L. L., HARRIS, T. B.,
SMITH, A. V., SHULDINER, A. R., MCARDLE, W. L., CAULFIELD, M. J.,
MUNROE, P. B., GRONBERG, H., CHEN, Y. D., LI, G., BECKMANN,
J. S., JOHNSON, T., THORSTEINSDOTTIR, U., TEDER-LAVING, M., KHAW,
K. T., WAREHAM, N. J., ZHAO, J. H., AMIN, N., OOSTRA, B. A.,
KRAJA, A. T., PROVINCE, M. A., CUPPLES, L. A., HEARD-COSTA, N. L.,
KAPRIO, J., RIPATTI, S., SURAKKA, I., COLLINS, F. S., SARAMIES, J.,
TUOMILEHTO, J., JULA, A., SALOMAA, V., ERDMANN, J., HENGSTEN-
BERG, C., LOLEY, C., SCHUNKERT, H., LAMINA, C., WICHMANN, H. E.,
ALBRECHT, E., GIEGER, C., HICKS, A. A., JOHANSSON, A., PRAM-
STALLER, P. P., KATHIRESAN, S., SPELIOTES, E. K., PENNINX, B., HAR-
TIKAINEN, A. L., JARVELIN, M. R., GYLLENSTEN, U., BOOMSMA, D. I.,
CAMPBELL, H., WILSON, J. F., CHANOCK, S. J., FARRALL, M., GOEL, A.,
MEDINA-GOMEZ, C., RIVADENEIRA, F., ESTRADA, K., UITTERLINDEN,
A. G., HOFMAN, A., ZILLIKENS, M. C., DEN HEIJER, M., KIEMENEY,
L. A., MASCHIO, A., HALL, P., TYRER, J., TEUMER, A., VOLZKE, H.,
KOVACS, P., TONJES, A., MANGINO, M., SPECTOR, T. D., HAYWARD, C.,
RUDAN, I., HALL, A. S., SAMANI, N. J., ATTWOOD, A. P., SAMBROOK,
J. G., HUNG, J., PALMER, L. J., LOKKI, M. L., SINISALO, J., BOUCHER,
G., HUIKURI, H., LORENTZON, M., OHLSSON, C., EKLUND, N., ERIKS-
SON, J. G., BARLASSINA, C., RIVOLTA, C., NOLTE, I. M., SNIEDER, H.,
113
VAN DER KLAUW, M. M., VAN VLIET-OSTAPTCHOUK, J. V., GEJMAN,
P. V., SHI, J., JACOBS, K. B., WANG, Z., BAKKER, S. J., MATEO LEACH,
I., NAVIS, G., VAN DER HARST, P., MARTIN, N. G., MEDLAND, S. E.,
MONTGOMERY, G. W., YANG, J., CHASMAN, D. I., RIDKER, P. M., ROSE,
L. M., LEHTIMAKI, T., RAITAKARI, O., ABSHER, D., IRIBARREN, C.,
BASART, H., HOVINGH, K. G., HYPPONEN, E., POWER, C., ANDER-
SON, D., BEILBY, J. P., HUI, J., JOLLEY, J., SAGER, H., BORNSTEIN,
S. R., SCHWARZ, P. E., KRISTIANSSON, K., PEROLA, M., LINDSTROM,
J., SWIFT, A. J., UUSITUPA, M., ATALAY, M., LAKKA, T. A., RAURAMAA,
R., BOLTON, J. L., FOWKES, G., FRASER, R. M., PRICE, J. F., FISCHER,
K., KRJUTA KOV, K., METSPALU, A., MIHAILOV, E., LANGENBERG,
C., LUAN, J., ONG, K. K., CHINES, P. S., KEINANEN-KIUKAANNIEMI,
S. M., SAARISTO, T. E., EDKINS, S., FRANKS, P. W., HALLMANS, G.,
SHUNGIN, D., MORRIS, A. D., PALMER, C. N., ERBEL, R., MOEBUS, S.,
NOTHEN, M. M., PECHLIVANIS, S., HVEEM, K., NARISU, N., HAMSTEN,
A., HUMPHRIES, S. E., STRAWBRIDGE, R. J., TREMOLI, E., GRALLERT,
H., THORAND, B., ILLIG, T., KOENIG, W., MULLER-NURASYID, M., PE-
TERS, A., BOEHM, B. O., KLEBER, M. E., MARZ, W., WINKELMANN,
B. R., KUUSISTO, J., LAAKSO, M., ARVEILER, D., CESANA, G., KUU-
LASMAA, K., VIRTAMO, J., YARNELL, J. W., KUH, D., WONG, A., LIND,
L., DE FAIRE, U., GIGANTE, B., MAGNUSSON, P. K., PEDERSEN, N. L.,
DEDOUSSIS, G., DIMITRIOU, M., KOLOVOU, G., KANONI, S., STIRRUPS,
K., BONNYCASTLE, L. L., NJOLSTAD, I., WILSGAARD, T., GANNA, A.,
REHNBERG, E., HINGORANI, A., KIVIMAKI, M., KUMARI, M., ASSIMES,
T. L., BARROSO, I., BOEHNKE, M., BORECKI, I. B., DELOUKAS, P., FOX,
C. S., FRAYLING, T., GROOP, L. C., HARITUNIANS, T., HUNTER, D., IN-
GELSSON, E., KAPLAN, R., MOHLKE, K. L., O’CONNELL, J. R., SCH-
LESSINGER, D., STRACHAN, D. P., STEFANSSON, K., VAN DUIJN, C. M.,
ABECASIS, G. R., MCCARTHY, M. I., HIRSCHHORN, J. N., QI, L., LOOS,
R. J., LINDGREN, C. M., NORTH, K. E., AND HEID, I. M. Sex-stratified
genome-wide association studies including 270,000 individuals show sex-
ual dimorphism in genetic loci for anthropometric traits. PLoS Genet 9, 6
(2013), e1003500.
[117] REPPELL, M., BOEHNKE, M., AND ZOLLNER, S. FTEC: a coalescent sim-
ulator for modeling faster than exponential growth. Bioinformatics 28, 9
(2012), 1282–1283.
[118] REPPELL, M., BOEHNKE, M., AND ZOLLNER, S. The impact of accel-
erating faster than exponential population growth on genetic variation.
Genetics 196, 3 (2014), 819–828.
[119] ROACH, J. C., GLUSMAN, G., SMIT, A. F., HUFF, C. D., HUBLEY, R.,
114
SHANNON, P. T., ROWEN, L., PANT, K. P., GOODMAN, N., BAMSHAD,
M., SHENDURE, J., DRMANAC, R., JORDE, L. B., HOOD, L., AND GALAS,
D. J. Analysis of genetic inheritance in a family quartet by whole-genome
sequencing. Science 328, 5978 (2010), 636–639.
[120] SCALLY, A., AND DURBIN, R. Revising the human mutation rate: impli-
cations for understanding human evolution. Nat Rev Genet 13, 10 (2012),
745–753.
[121] SCHIFFELS, S., AND DURBIN, R. Inferring human population size and
separation history from multiple genome sequences. Nat Genet 46, 8
(2014), 919–925.
[122] SHEEHAN, S., HARRIS, K., AND SONG, Y. S. Estimating variable effective
population sizes from multiple genomes: a sequentially markov condi-
tional sampling distribution approach. Genetics 194, 3 (2013), 647–662.
[123] STOUFFER, S. A. The American soldier. Studies in social psychology in
World War II. Princeton University Press, Princeton, 1949.
[124] TAKAHATA, N., AND NEI, M. Gene genealogy and variance of interpop-
ulational nucleotide differences. Genetics 110, 2 (1985), 325–344.
[125] TAVARE, S. Line-of-descent and genealogical processes, and their applica-
tions in population-genetics models. Theor Pop Biol 26, 2 (1984), 119–164.
[126] TAYLOR, P. N., PORCU, E., CHEW, S., CAMPBELL, P. J., TRAGLIA, M.,
BROWN, S. J., MULLIN, B. H., SHIHAB, H. A., MIN, J., WALTER, K.,
MEMARI, Y., HUANG, J., BARNES, M. R., BEILBY, J. P., CHAROEN,
P., DANECEK, P., DUDBRIDGE, F., FORGETTA, V., GREENWOOD, C.,
GRUNDBERG, E., JOHNSON, A. D., HUI, J., LIM, E. M., MCCARTHY, S.,
MUDDYMAN, D., PANICKER, V., PERRY, J. R., BELL, J. T., YUAN, W.,
RELTON, C., GAUNT, T., SCHLESSINGER, D., ABECASIS, G., CUCCA, F.,
SURDULESCU, G. L., WOLTERSDORF, W., ZEGGINI, E., ZHENG, H. F.,
TONIOLO, D., DAYAN, C. M., NAITZA, S., WALSH, J. P., SPECTOR, T.,
DAVEY SMITH, G., DURBIN, R., RICHARDS, J. B., SANNA, S., SORANZO,
N., TIMPSON, N. J., WILSON, S. G., AND THE UK10K CONSORTIUM.
Whole-genome sequence-based analysis of thyroid function. Nat Commun
6 (2015), 5681.
[127] TENNESSEN, J. A., BIGHAM, A. W., O’CONNOR, T. D., FU, W., KENNY,
E. E., GRAVEL, S., MCGEE, S., DO, R., LIU, X., JUN, G., KANG, H. M.,
115
JORDAN, D., LEAL, S. M., GABRIEL, S., RIEDER, M. J., ABECASIS, G.,
ALTSHULER, D., NICKERSON, D. A., BOERWINKLE, E., SUNYAEV, S.,
BUSTAMANTE, C. D., BAMSHAD, M. J., AKEY, J. M., BROAD G O, SEAT-
TLE G O, AND NHLBI EXOME SEQUENCING PROJECT. Evolution and
functional impact of rare coding variation from deep sequencing of hu-
man exomes. Science 337, 6090 (2012), 64–69.
[128] TERHORST, J., AND SONG, Y. S. Fundamental limits on the accuracy of
demographic inference based on the sample frequency spectrum. Proc
Natl Acad Sci U S A 112, 25 (2015), 7677–7682.
[129] THE ACCORD STUDY GROUP, GINSBERG, H. N., ELAM, M. B., LOVATO,
L. C., CROUSE, J. R., R., LEITER, L. A., LINZ, P., FRIEDEWALD, W. T.,
BUSE, J. B., GERSTEIN, H. C., PROBSTFIELD, J., GRIMM, R. H., ISMAIL-
BEIGI, F., BIGGER, J. T., GOFF, D C, J., CUSHMAN, W. C., SIMONS-
MORTON, D. G., AND BYINGTON, R. P. Effects of combination lipid ther-
apy in type 2 diabetes mellitus. N Engl J Med 362, 17 (2010), 1563–1574.
[130] THORNTON, T., ZHANG, Q., CAI, X., OBER, C., AND MCPEEK, M. S.
XM: association testing on the X-chromosome in case-control samples
with related individuals. Genet Epidemiol 36, 5 (2012), 438–50.
[131] TRIGLYCERIDE CORONARY DISEASE GENETICS CONSORTIUM AND
EMERGING RISK FACTORS COLLABORATION, SARWAR, N., SANDHU,
M. S., RICKETTS, S. L., BUTTERWORTH, A. S., DI ANGELANTONIO, E.,
BOEKHOLDT, S. M., OUWEHAND, W., WATKINS, H., SAMANI, N. J.,
SALEHEEN, D., LAWLOR, D., REILLY, M. P., HINGORANI, A. D., TAL-
MUD, P. J., AND DANESH, J. Triglyceride-mediated pathways and coro-
nary disease: collaborative analysis of 101 studies. Lancet 375, 9726 (2010),
1634–1639.
[132] TRYKA, K. A., HAO, L., STURCKE, A., JIN, Y., WANG, Z. Y., ZIYABARI,
L., LEE, M., POPOVA, N., SHAROPOVA, N., KIMURA, M., AND FEOLO,
M. NCBI’s Database of Genotypes and Phenotypes: dbGaP. Nucleic Acids
Res 42, Database issue (2014), D975–D979.
[133] TUKIAINEN, T., PIRINEN, M., SARIN, A. P., LADENVALL, C., KET-
TUNEN, J., LEHTIMAKI, T., LOKKI, M. L., PEROLA, M., SINISALO, J.,
VLACHOPOULOU, E., ERIKSSON, J. G., GROOP, L., JULA, A., JARVELIN,
M. R., RAITAKARI, O. T., SALOMAA, V., AND RIPATTI, S. Chromosome
X-wide association study identifies Loci for fasting insulin and height and
evidence for incomplete dosage compensation. PLoS Genet 10, 2 (2014),
e1004127.
116
[134] UK IBD GENETICS CONSORTIUM, BARRETT, J. C., LEE, J. C., LEES,
C. W., PRESCOTT, N. J., ANDERSON, C. A., PHILLIPS, A., WESLEY, E.,
PARNELL, K., ZHANG, H., DRUMMOND, H., NIMMO, E. R., MASSEY,
D., BLASZCZYK, K., ELLIOTT, T., COTTERILL, L., DALLAL, H., LOBO,
A. J., MOWAT, C., SANDERSON, J. D., JEWELL, D. P., NEWMAN, W. G.,
EDWARDS, C., AHMAD, T., MANSFIELD, J. C., SATSANGI, J., PARKES,
M., MATHEW, C. G., WELLCOME TRUST CASE CONTROL, C., DON-
NELLY, P., PELTONEN, L., BLACKWELL, J. M., BRAMON, E., BROWN,
M. A., CASAS, J. P., CORVIN, A., CRADDOCK, N., DELOUKAS, P., DUN-
CANSON, A., JANKOWSKI, J., MARKUS, H. S., MATHEW, C. G., MC-
CARTHY, M. I., PALMER, C. N., PLOMIN, R., RAUTANEN, A., SAWCER,
S. J., SAMANI, N., TREMBATH, R. C., VISWANATHAN, A. C., WOOD, N.,
SPENCER, C. C., BARRETT, J. C., BELLENGUEZ, C., DAVISON, D., FREE-
MAN, C., STRANGE, A., DONNELLY, P., LANGFORD, C., HUNT, S. E., ED-
KINS, S., GWILLIAM, R., BLACKBURN, H., BUMPSTEAD, S. J., DRONOV,
S., GILLMAN, M., GRAY, E., HAMMOND, N., JAYAKUMAR, A., MC-
CANN, O. T., LIDDLE, J., PEREZ, M. L., POTTER, S. C., RAVINDRARA-
JAH, R., RICKETTS, M., WALLER, M., WESTON, P., WIDAA, S., WHIT-
TAKER, P., DELOUKAS, P., PELTONEN, L., MATHEW, C. G., BLACKWELL,
J. M., BROWN, M. A., CORVIN, A., MCCARTHY, M. I., SPENCER, C. C.,
ATTWOOD, A. P., STEPHENS, J., SAMBROOK, J., OUWEHAND, W. H.,
MCARDLE, W. L., RING, S. M., AND STRACHAN, D. P. Genome-wide
association study of ulcerative colitis identifies three new susceptibility
loci, including the HNF4A region. Nat Genet 41, 12 (2009), 1330–1334.
[135] VAN RAALTE, D. H., LI, M., PRITCHARD, P. H., AND WASAN, K. M. Per-
oxisome proliferator-activated receptor (PPAR)-alpha: a pharmacological
target with a promising future. Pharm Res 21, 9 (2004), 1531–1538.
[136] VOSKUHL, R. Sex differences in autoimmune diseases. Biol Sex Differ 2, 1
(2011), 1.
[137] WAKELEY, J., AND HEY, J. Estimating ancestral population parameters.
Genetics 145, 3 (1997), 847–855.
[138] WELTER, D., MACARTHUR, J., MORALES, J., BURDETT, T., HALL, P.,
JUNKINS, H., KLEMM, A., FLICEK, P., MANOLIO, T., HINDORFF, L.,
AND PARKINSON, H. The NHGRI GWAS Catalog, a curated resource of
SNP-trait associations. Nucleic Acids Res 42, Database issue (2014), D1001–
D1006.
[139] WILLER, C. J., LI, Y., AND ABECASIS, G. R. METAL: fast and effi-
cient meta-analysis of genomewide association scans. Bioinformatics 26,
117
17 (2010), 2190–2191.
[140] WILLIAMS, O. D. The atherosclerosis risk in communities (aric) study -
design and objectives. American Journal of Epidemiology 129, 4 (1989), 687–
702.
[141] WILSON, M. A., AND MAKOVA, K. D. Genomic analyses of sex chromo-
some evolution. Annu Rev Genomics Hum Genet 10 (2009), 333–354.
[142] WISE, A. L., GYI, L., ANDMANOLIO, T. A. eXclusion: toward integrating
the X chromosome in genome-wide association analyses. Am J Hum Genet
92, 5 (2013), 643–647.
[143] WU, M. C., LEE, S., CAI, T., LI, Y., BOEHNKE, M., AND LIN, X. Rare-
variant association testing for sequencing data with the sequence kernel
association test. Am J Hum Genet 89, 1 (2011), 82–93.
[144] ZAITLEN, N., PASANIUC, B., PATTERSON, N., POLLACK, S., VOIGHT,
B., GROOP, L., ALTSHULER, D., HENDERSON, B. E., KOLONEL, L. N.,
LE MARCHAND, L., WATERS, K., HAIMAN, C. A., STRANGER, B. E.,
DERMITZAKIS, E. T., KRAFT, P., AND PRICE, A. L. Analysis of case-
control association studies with known risk variants. Bioinformatics 28,
13 (2012), 1729–1737.
[145] ZAYKIN, D. V., ZHIVOTOVSKY, L. A., WESTFALL, P. H., AND WEIR, B. S.
Truncated product method for combining P-values. Genet Epidemiol 22, 2
(2002), 170–185.
[146] ZHANG, J., WHEELER, D. A., YAKUB, I., WEI, S., SOOD, R., ROWE, W.,
LIU, P. P., GIBBS, R. A., AND BUETOW, K. H. SNPdetector: a software
tool for sensitive and accurate SNP detection. PLoS Comput Biol 1, 5 (2005),
e53.
[147] ZHENG, G., JOO, J., ZHANG, C., AND GELLER, N. L. Testing association
for markers on the X chromosome. Genet Epidemiol 31, 8 (2007), 834–843.
118
